Ashland (ASH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Ashland (ASH) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 04/30/2025
|
Ashland (ASH) Lags Q2 Earnings and Revenue Estimates
- Ashland (ASH) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.27 per share a year ago.
- 04/30/2025
|
Ashland reports second quarter fiscal 2025 results and revises full-year outlook
- WILMINGTON, Del., April 30, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the second quarter of fiscal year 2025, which ended March 31, 2025, and revised its full-year fiscal 2025 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.
- 04/30/2025
|
Ashland Place Completes Two New Financing Facilities for Sirius Aviation Capital
- NEW YORK , April 29, 2025 /PRNewswire/ -- Ashland Place Finance LLC ("Ashland Place"), a commercial aviation financing platform, today announced the completion of two new facilities for Sirius Aviation Capital Holdings Limited ("Sirius"), a global aircraft lessor based in Abu Dhabi Global Market. Both A320-200s, the aircraft are currently operating on lease to ANA's Peach Aviation Limited ("Peach") in Japan and Controladora Vuela Compañía de Aviación, S.A.B.
- 04/29/2025
|
Earnings Preview: Ashland (ASH) Q2 Earnings Expected to Decline
- Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/23/2025
|
Ashland sets date for second-quarter fiscal 2025 earnings release and conference call webcast
- WILMINGTON, Del., April 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its second-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Wednesday, April 30, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Thursday, May 1. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.
- 04/17/2025
|
Ashland Wraps Up Expansion of Pharmaceutical Plant in Brazil
- ASH is investing in modernizing equipment for microbial protection in personal care applications at its Technical Center in Sao Paulo.
- 04/03/2025
|
Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest
- Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China
- 04/01/2025
|
Ashland to host 2025 Innovation Day for analysts and investors
- WILMINGTON, Del., March 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is hosting an Innovation Day for analysts and investors at the company's Bridgewater, New Jersey facility, Thursday, May 29, 2025. The event will showcase the enhanced capabilities and expanded applications of Ashland's scalable technology platforms. Registration is required, with options to attend via live webcast or in person.
- 03/28/2025
|
Ashland Wraps Up Divestment of Avoca Business to Mane
- ASH closes the sales of its Avoca business, the last entity remaining from the Pharmachem acquisition.
- 03/18/2025
|
Ashland completes sale of Avoca business to Mane
- Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed.
- 03/17/2025
|
Ashland Presents Attractive Upside Emerging From The Downcycle
- Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 months, Ashland's strategic acquisitions and divestitures have strengthened its market position, with a focus on high-margin, patent-protected products. Ashland's strong balance sheet, low leverage, and fixed-rate debt provide stability and flexibility to navigate the current downcycle in the specialty chemicals sector.
- 02/27/2025
|
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
- TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism.
- 02/10/2025
|
Ashland's Earnings Outpace Estimates, Revenues Miss in Q1
- Organic sales volume growth in ASH's Personal Care, Specialty Additives and Intermediates segments largely offset lower volumes in Life Sciences in Q1.
- 01/30/2025
|
Ashland Inc. (ASH) Q1 2025 Earnings Call Transcript
- Ashland Inc. (NYSE:ASH ) Q1 2025 Earnings Conference Call January 29, 2025 9:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo Chris Parkinson - Wolfe Research John Roberts - Mizuho David Begleiter - Deutsche Bank Jeff Zekauskas - JPMorgan Mike Harrison - Seaport Research Partners Bhavesh Lodaya - BMO Capital Markets Josh Spector - UBS Operator Good day and thank you for standing by. Welcome to the Ashland Inc. First Quarter 2025 Earnings Conference Call.
- 01/29/2025
|
New Strong Sell Stocks for January 29th
- ARCAY, ASH and DNKEY have been added to the Zacks Rank #5 (Strong Sell) List on January 29, 2024.
- 01/29/2025
|
Here's What Key Metrics Tell Us About Ashland (ASH) Q1 Earnings
- Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 01/28/2025
|
Ashland (ASH) Surpasses Q1 Earnings Estimates
- Ashland (ASH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.45 per share a year ago.
- 01/28/2025
|
Ashland reports financial results for first quarter fiscal 20251, reiterates outlook for full-year fiscal 2025
- WILMINGTON, Del., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the first quarter of fiscal year 2025, which ended December 31, 2024, and issued its full-year fiscal 2025 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.
- 01/28/2025
|
Stay Ahead of the Game With Ashland (ASH) Q1 Earnings: Wall Street's Insights on Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Ashland (ASH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
- 01/23/2025
|
Forget The S&P 500 - 3 Small Dividend Stocks At Big Discounts
- President Trump inherits a historically expensive stock market, with the Shiller P/E ratio indicating potentially subdued long-term returns for the S&P 500. Despite high valuations, opportunities exist, especially in smaller and mid-cap stocks, which are undervalued compared to large-cap stocks. The market's top-heavy nature, driven by FANG+ stocks, presents a risk/reward shift, making smaller companies more attractive.
- 01/23/2025
|
Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for
- Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/21/2025
|
Ashland board authorizes quarterly dividend
- WILMINGTON, Del., Jan. 20, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on March 15, 2025, to stockholders of record at the close of business on March 1, 2025.
- 01/20/2025
|
Bear of the Day: Ashland Inc (ASH)
- This stock does not have the best looking chart and has seen estimates continue to fall.
- 01/16/2025
|
Ashland sets date for first-quarter fiscal 2025 earnings release and conference call webcast
- WILMINGTON, Del., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, January 28, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, January 29. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.
- 01/14/2025
|
New Strong Sell Stocks for January 7th
- ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024.
- 01/07/2025
|
Ashland Inks Deal to Sell Avoca Business to Optimize Portfolio
- ASH is set to sell off its remaining Sclareolide business through the divestiture of Avoca to Mane.
- 12/30/2024
|
Hematology Oncology of Indiana Physician Research Presented at 66th ASH Annual Meeting
- INDIANAPOLIS, IN., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Board-certified medical oncologists, M. Sarfraz Nawaz, MD and Ruemu E. Birhiray, MD from community oncology practice Hematology Oncology of Indiana (HOI), a partner practice of American Oncology Network (AON) (OTCQX: AONC), presented clinically meaningful and socially impactful research findings at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held Dec. 7-10 in San Diego.
- 12/30/2024
|
Ashland signs definitive agreement to sell Avoca business to Mane
- Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions.
- 12/23/2024
|
New Strong Sell Stocks for November 18th
- ASH, ARW and AN have been added to the Zacks Rank #5 (Strong Sell) List on November 18, 2024.
- 12/18/2024
|
Ashland price target lowered to $85 from $100 at Evercore ISI
- Evercore ISI analyst Eric Boyes lowered the firm's price target on Ashland to $85 from $100 and keeps an In Line rating on the shares as a new analyst took over coverage of the stock and 10 other chemical names. Dissonance between sputtering industrial demand into year-end and prospects for a "less bad" 2025 has "muddled the forward outlook for chemicals investors" and the firm's sense is further EBITDA and EPS cuts coming to Q1 and FY25 "are needed to clear the deck," the analyst says. However, Evercore suspects the stocks "move sharply higher with signs of improving demand, so begin to position accordingly," the analyst added.
- 12/17/2024
|
Ashland: A Stable Stock Trading At 50% Discount To Its Intrinsic Value
- Ashland Inc. (NYSE: ASH) offers a promising upside of 58.3% with a target price of $125.72, driven by its strong financial fundamentals and growth potential in biotechnology. The company is well-diversified, primarily serving the pharmaceutical and cosmetic industries, which account for over two-thirds of its revenue. Despite a modest 2% dividend yield, Ashland consistently pays dividends and has a history of share buybacks, signaling shareholder commitment.
- 12/12/2024
|
New Strong Sell Stocks for December 12th
- ASH, BIDU and EVH have been added to the Zacks Rank #5 (Strong Sell) List on December 12, 2024.
- 12/12/2024
|
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
- ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis, in an Oral Report at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
- 12/10/2024
|
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
- ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the follow-up safety and efficacy data of the company's investigational Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in combination with azacitidine (AZA) for the treatment of patients with myelodysplastic syndrome (MDS), in a Poster Presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
- 12/10/2024
|
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
- ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of lisaftoclax (APG-2575) as a monotherapy or in combinations in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), in a Poster Presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
- 12/10/2024
|
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
- Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up
- 12/09/2024
|
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
- SOUTH SAN FRANCISCO, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced initial positive clinical data from the multi-center Phase 1-2 study of IMPT-314 in patients with large B-cell lymphoma that is being presented at the 66th American Society of Hematology (ASH) Annual Meeting. IMPT-314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate being developed for patients with aggressive B-cell non-Hodgkin lymphoma.
- 12/09/2024
|
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
- LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting, being held from December 7-10, 2024, in San Diego. “Our oral presentation at ASH this year with data from the FELIX trial demonstrates that obe-cel treatment produces a high incidence of deep molecular remission in r/r adult ALL patients, which correlates with better outcomes and is associated with longer event free survival (EFS) and overall survival (OS),” said Dr. Christian Itin, Chief Executive Officer of Autolus.
- 12/09/2024
|
New and Updated Data for Genentech's Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody program were presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, December 7-10, 2024. With more than 20 bispecific antibody abstracts accepted for presentation, data showcase the benefits of fixed-duration Columvi® (glofitamab-gxbm.
- 12/09/2024
|
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
- PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline.
- 12/09/2024
|
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
- Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial
- 12/09/2024
|
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
- Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib prolonged the time to next treatment or death by a median of 23.9 months compared to 10.9 months in the control arm BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor INDIANAPOLIS , Dec. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The study's primary endpoint of progression-free survival (PFS) was met at primary analysis1, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR), based on independent review committee (IRC) assessment.
- 12/09/2024
|
Ashland rings opening bell at NYSE recognizes 100-year anniversary
- Wilmington, Del., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Participating in a tradition that has evolved since 1792, today, employees from Ashland Inc. (NYSE: ASH) gathered on the floor of the New York Stock Exchange as Guillermo Novo, chair and chief executive officer, Ashland, joined by company executives, rang the trading day's opening bell.
- 12/09/2024
|
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
- ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd alone New detailed results from the GMMG-HD7 phase 3 study of Sarclisa-RVd induction therapy resulted in a significant and clinically meaningful PFS benefit with deeper MRD negativity in transplant-eligible NDMM patients Results support the benefit of Sarclisa-based combinations to patients in the front-line setting and the ongoing use of MRD negativity as a potential surrogate endpoint for PFS in MM research Paris, December 9, 2024. New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, CA, US.
- 12/09/2024
|
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
- R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD SOUTH SAN FRANCISCO, Calif. , Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS).
- 12/09/2024
|
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
- TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. Sites TUS and TUS+VEN Broadly Active Across AML Populations, with Favorable Safety TUS-based therapies are active in FLT3 wildtype, representing ~70% of AML patients TUS Targets VEN Resistance Mechanisms, Enabling TUS+VEN to Achieve Responses in Difficult-to-treat Prior-VEN Failure AML SAN DIEGO and TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today featured a wealth of clinical data for Aptose's lead compound tuspetinib (TUS) in a poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. Poster title: “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML” Key Findings and Messages: TUS+VEN+AZA triplet trial is proceeding in newly diagnosed AML patients TUS+VEN retains activity in the difficult-to-treat prior-VEN AML population TUS+VEN is active in FLT3 wildtype, representing ~70% of AML patients TUS+VEN is well tolerated and can be safely co-administered TUS+VEN is active across broad populations of R/R AML Combination of TUS with VEN may avoid VEN resistance TUS+VEN+AZA triplet may establish a more effective, mutation agnostic standard of care for chemotherapy ineligible AML patients Tuspetinib (TUS), being developed by Aptose and originally created by Hanmi Pharmaceutical Co., is being advanced as the TUS+VEN+AZA triplet (tuspetinib+venetoclax+azacitidine) for frontline therapy of newly diagnosed AML patients ineligible for intensive chemotherapy.
- 12/09/2024
|
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
- -Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol-
- 12/09/2024
|
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
- WATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ASH 2024 annual meeting in San Diego, CA. This year's presentations included updates from the BEACON and AURORA trials of bitopertin in patients with erythropoietic protoporphyria (EPP) and the Phase 1 SAD/MAD trial of DISC-3405 in healthy volunteers. Additionally, Disc presented a real-world patient survey highlighting the disease burden of EPP and multiple preclinical models highlighting the potential benefits of bitopertin, DISC-0974, and DISC-3405 in existing and new indications. The collection of data supports Disc's continued advancement of all three clinical candidates and provides evidence for expansion opportunities in new indications.
- 12/09/2024
|
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
- Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m.
- 12/09/2024
|
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
- Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups New preclinical data supports P-CD19CD20-ALLO1's strong anti-cancer profile and the ongoing Phase 1 clinical trial Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence SAN DIEGO , Dec. 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today will highlight interim clinical data from its Phase 1 trial of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma (RRMM), including new profiling of patient responses from Arm C, an optimized lymphodepletion arm. The P-BCMA-ALLO1 data are being presented, along with two additional Company poster presentations covering new preclinical data for P-CD19CD20-ALLO1 and a patient case study demonstrating the reactivation of a Poseida autologous CAR-T therapy with a T-cell engager, at the 66th ASH Annual Meeting and Exposition being held in San Diego on December 7-10, 2024.
- 12/09/2024
|
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
- LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California. “Additional divesiran data pres.
- 12/09/2024
|
Ashland celebrates solvers, recognizes 100 years of innovation by planting trees to restore local ecosystems and support sustainable sourcing
- Wilmington, Del., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), the global additives and specialty ingredients company today announced a strategic partnership with the Arbor Day Foundation, recognizing the 100-year anniversary of the company and celebrating the innovative work of its global solvers.
- 12/09/2024
|
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
- MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The TELLOMAK study addresses a critical unmet need for p.
- 12/09/2024
|
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
- NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F
- 12/08/2024
|
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable cli.
- 12/08/2024
|
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
- – ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –
- 12/08/2024
|
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
- SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral presentation on Sunday, December 8 at 9:30 a.m. Pacific Time and a poster presentation on Sunday, December 8 at 6 p.
- 12/08/2024
|
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
- In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels
- 12/08/2024
|
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
- SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were presented at 66th American Society of Hematology (ASH) Annual Meeting & Exposition. The data include findings from the largest real-world analysis of patients who received Yescarta as second-line trea.
- 12/08/2024
|
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
- New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL
- 12/07/2024
|
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
- – 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – – 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – – Responses were rapid, durable and observed across all major subgroups in expanded dataset ofPh 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – – Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting – WALTHAM, Mass. , Dec. 7, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presented positive data from multiple trials of Revuforj® (revumenib) as a single-agent and in combination with standard of care agents in patients with acute leukemias in oral sessions at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, December 7-10, 2024.
- 12/07/2024
|
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
- -- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM -- -- Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT -- CAMBRIDGE, Mass. , Dec. 7, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the company's ongoing partnership with the SM community to redefine the future of patient care – from improving diagnostic rates to raising the bar on treatment outcomes.
- 12/07/2024
|
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
- NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego, California.
- 12/07/2024
|
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
- All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
- 12/07/2024
|
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
- ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
- 12/07/2024
|
BostonGene Announces Twelve Abstracts Selected for Presentation at the 66th American Society of Hematology Annual Meeting & Exposition
- WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of 10 abstracts for poster presentations and two abstracts for online publication at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 7-10, 2024, in San Diego, California. BostonGene will exhibit in booth #1955. “We are excited to present our research findings at ASH that underscores the trans.
- 12/06/2024
|
K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Meeting
- Results collectively support the mechanism of action and rationale for targeting MMSET in patients with multiple myeloma CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET / NSD2 inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced upcoming poster presentations outlining data from its KTX-1001 and KTX-1029 programs at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-10, 2024 in San Diego, California.
- 12/03/2024
|
Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting
- Bagsværd, Denmark, 3 December 2024 – Novo Nordisk today announced the presentation of 13 abstracts, three of which will be presented in oral sessions, at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 December 2024 in San Diego, California.
- 12/03/2024
|
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
- SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2024, in San Diego. Among these abstracts are a plenary session presentation, a late-breaking abstract and 25 other oral presentations.
- 12/03/2024
|
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
- MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET® asset, have been selected for the American Society of hematology (ASH) Annual Meeting. “We are proud of the progress being made across our multiple programs, including our lead proprietary asset l.
- 12/03/2024
|
Kura Oncology to Host Virtual Investor Event on December 9, 2024
- Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH
- 12/02/2024
|
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
- SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton's tyrosine kinase (BTK) degrader program NX-5948, and provide a corporate update, at 8:15 p.m. PT (11:15 p.m. ET) on Monday, December 9, 2024.
- 12/02/2024
|
New Strong Sell Stocks for November 26th
- AHEXY, WMS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2024.
- 11/26/2024
|
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
- 75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that additional NEXICART-1 NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 7-10, 2024. “NXC-201 is the only CAR-T in development for relapsed/refractory AL amyloidosis patients,” said Ilya Rachman, MD PhD, Chief Executive Officer of Immix Biopharma.
- 11/25/2024
|
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
- RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from Dec. 7-10. Data being shared at the meeting will showcase the company's continued progress in advancing clinical research for Merck's expanding and diverse pipeline of inv.
- 11/21/2024
|
Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
- PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--BMS' Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms.
- 11/19/2024
|
Ashland board authorizes quarterly dividend
- WILMINGTON, Del., Nov. 14, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on December 15, 2024, to stockholders of record at the close of business on December 1, 2024.
- 11/14/2024
|
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
- Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria
- 11/13/2024
|
Ashland's Earnings Miss in Q4, Revenues Surpass Estimates
- ASH sees higher sales volumes in Personal Care, Specialty Additives and Intermediates segments in Q4.
- 11/12/2024
|
Ashland Place Completes New Financing Facility for Crestone Air Partners, Air T, Inc. and Mill Road Capital
- NEW YORK , Nov. 12, 2024 /PRNewswire/ -- Ashland Place Finance LLC ("Ashland Place"), a commercial aviation financing platform, today announced the completion of a new facility financing the acquisition of a Boeing 737-800 for Crestone Air Partners, Inc. ("Crestone"), Air T, Inc. ("Air T") and Mill Road Capital Management LLC ("Mill Road"). This is the third transaction that the Ashland Place platform has completed with Crestone, having previously financed the acquisitions of three Boeing 737-800 freighters in January 2024 and four CFM56 engines in July 2022.
- 11/12/2024
|
Ashland Inc. (ASH) Q4 2024 Earnings Call Transcript
- Ashland Inc. (NYSE:ASH ) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - SVP and CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo James Cannon - UBS John Roberts - Mizuho Mike Harrison - Seaport Research Partners Operator Thank you for standing by. My name is Hermione and I will be your conference operator today.
- 11/09/2024
|
Ashland to host live 2024 strategy update event for analysts and investors
- WILMINGTON, Del., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a strategy update event for analysts and investors on Tuesday, December 10, 2024, in New York City. The company will provide an in-depth review of Ashland's strategic priorities, key initiatives and financial objectives while emphasizing a proactive approach to market uncertainty in fiscal year 2025.
- 11/08/2024
|
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
- Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study
- 11/07/2024
|
Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Ashland (ASH) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 11/06/2024
|
Ashland (ASH) Q4 Earnings Lag Estimates
- Ashland (ASH) came out with quarterly earnings of $1.26 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.41 per share a year ago.
- 11/06/2024
|
ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
- ROCKVILLE, Md. and SUZHOU, China , Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the latest results from three clinical studies of one of the company's key drug candidate, lisaftoclax (APG-2575), have been selected for presentations, including an Oral Report, at the 66th American Society of Hematology (ASH) Annual Meeting.
- 11/06/2024
|
ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
- ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the latest results from three clinical studies of one of the company's key drug candidate, lisaftoclax (APG-2575), have been selected for presentations, including an Oral Report, at the 66th American Society of Hematology (ASH) Annual Meeting.
- 11/06/2024
|
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
- NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting being held in San Diego from December 7-10, 2024. ASH Presentation Details: Presenting author: Aaron Gerds, MD (Cleveland Clinic) Publication Number: 4559 Title: Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV) Session Name: 634.
- 11/05/2024
|
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
- Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 7-10 December 2024.
- 11/05/2024
|
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
- COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin's lymphoma (NHL) patients New and updated data from EPCORE® clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple B-cell malignancies across lines of therapy Genmab A/S (Nasdaq: GMAB) announced today more than 20 abstracts evaluating epc.
- 11/05/2024
|
Unveiling Ashland (ASH) Q4 Outlook: Wall Street Estimates for Key Metrics
- Evaluate the expected performance of Ashland (ASH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 11/05/2024
|
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
- - Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure –
- 11/05/2024
|
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
- SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced that an abstract highlighting initial clinical data from the Phase 1-2 study of IMPT-314 in large B-cell lymphoma will be presented by Sarah M. Larson, M.D., Associate Professor, Department of Medicine, Medical Director, Immune Effector Cell Therapy Program, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, at the 66th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA, December 7 – 10, 2024. IMPT-314 is a dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate being developed for patients with aggressive B-cell non-Hodgkin's lymphoma.
- 11/05/2024
|
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
- CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma
- 11/05/2024
|
Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, 2024 in San Diego, California. The data underscore Genentech's commitment to advance patient outcomes in lymphoma with long-term follow-up of its approved medicines Polivy® (polatuzumab vedotin-pii.
- 11/05/2024
|
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
- – Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –
- 11/05/2024
|
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
- – Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (AG-946), the company's PK activators, will be featured in oral and poster presentations during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 7-10, 2024.
- 11/05/2024
|
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
- SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio presenting data from gene therapy programs in Sickle Cell Disease and Beta-Thalassemia at the 66th ASH Annual Meeting and Exposition.
- 11/05/2024
|
Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
- INDIANAPOLIS , Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place Dec. 7-10 in San Diego. In an oral presentation, Lilly will report results from the Phase 3 BRUIN CLL-321 study, which is evaluating pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
- 11/05/2024
|
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
- WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 9, 2024, at 7:00 a.m.
- 11/05/2024
|
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
- – Rapid responses and symptom improvement observed in inflammatory and fibrotic manifestations of chronic GVHD in heavily pretreated patients – WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX), today announced that multiple abstracts evaluating Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody for the treatment of chronic graft-versus-host disease (GVHD), have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California, December 7-10, 2024.
- 11/05/2024
|
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
- – New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile – – 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute leukemia in Ph 2 AUGMENT-101 pivotal cohort – – 88% ORR (23/26) in SAVE trial testing revumenib, venetoclax and decitabine/cedazuridine combination in R/R AML – WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California, December 7-10, 2024.
- 11/05/2024
|
Ashland (ASH) Reports Next Week: Wall Street Expects Earnings Growth
- Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/30/2024
|
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
- CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH).
- 10/29/2024
|
Ashland sets date for fourth-quarter fiscal 2024 earnings release and conference call webcast
- WILMINGTON, Del., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2024 earnings release at approximately 5 p.m. ET on Wednesday, November 6, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Thursday, November 7. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com .
- 10/28/2024
|
D.A. Davidson Acts as Exclusive Financial Advisor to Turnspire Capital Partners for Debt Financing in Support of Turnspire's Acquisition of Pharmachem
- NEW YORK--(BUSINESS WIRE)--D.A. Davidson & Co. announced today that it served as exclusive financial advisor to Turnspire Capital Partners LLC (“Turnspire”) on an asset-backed credit facility to finance Turnspire's acquisition of Pharmachem Innovations, LLC (“Pharmachem” or the “Company”), the former nutraceuticals business of Ashland Inc. (NYSE: ASH). “We appreciate the D.A. Davidson team's efforts in securing an attractive financing package for a complicated carve-out transaction, which e.
- 09/19/2024
|
Ashland Boosts the Application of Super Wetting Technology
- ASH's technology enables agricultural retailers to increase crop yield, facilitating organic growth.
- 09/18/2024
|
Ashland Wraps Up Nutraceuticals Business Sale to Turnspire Affiliate
- ASH's nutraceuticals business provides nutrition product producers with a diverse selection of active ingredients and formulation aids.
- 09/04/2024
|
Ashland completes sale of nutraceuticals business
- WILMINGTON, Del., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced it has completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC (“Turnspire”) effective August 30, 2024. The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
- 09/03/2024
|
Here's Why Ashland (ASH) is a Strong Value Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 08/23/2024
|
Ashland board authorizes quarterly dividend
- WILMINGTON, Del., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on September 15, 2024, to stockholders of record at the close of business on September 1, 2024.
- 08/09/2024
|
ASH vs. NVZMY: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Chemical - Specialty stocks have likely encountered both Ashland (ASH) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?
- 08/08/2024
|
Why Ashland (ASH) is a Top Value Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 08/07/2024
|
Ashland's (ASH) Earnings Beat Estimates in Q3, Sales Lag
- Ashland's (ASH) Q3 sales are adversely impacted by reduced Life Sciences volumes and weaker pricing.
- 08/07/2024
|
Here's What Key Metrics Tell Us About Ashland (ASH) Q3 Earnings
- Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/06/2024
|
Ashland (ASH) Surpasses Q3 Earnings Estimates
- Ashland (ASH) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.23 per share a year ago.
- 08/06/2024
|
Ashland reports financial results1 for third quarter fiscal 2024, issues outlook for fourth quarter and full-year fiscal 2024
- WILMINGTON, Del., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the third quarter of fiscal year 2024, which ended June 30, 2024, and issued its outlook for fourth quarter and full-year fiscal 2024. The global additives and specialty ingredients company holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.
- 08/06/2024
|
Are Basic Materials Stocks Lagging ASHLAND INC (ASH) This Year?
- Here is how Ashland (ASH) and Fortuna Mining (FSM) have performed compared to their sector so far this year.
- 08/05/2024
|
Ashland (ASH) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Ashland (ASH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 07/31/2024
|
ASH or NVZMY: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Ashland (ASH) and Novozymes A/S (NVZMY). But which of these two stocks presents investors with the better value opportunity right now?
- 07/23/2024
|
ASH vs. NVZMY: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Chemical - Specialty sector might want to consider either Ashland (ASH) or Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/22/2024
|
Are Basic Materials Stocks Lagging Aris Mining Corporation (ARMN) This Year?
- Here is how Aris Mining Corporation (ARMN) and Ashland (ASH) have performed compared to their sector so far this year.
- 07/18/2024
|
Ashland sets date for fiscal 2024 third-quarter earnings release and conference call webcast
- WILMINGTON, Del., July 17, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its third-quarter earnings release at approximately 5 p.m. ET on Tuesday, August 6, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Wednesday, August 7. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com .
- 07/17/2024
|
Ashland achieves certification by Fair Wage Network
- WILMINGTON, Del., June 18, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has strengthened its performance towards environmental, social and governance (ESG) practices and a more just and equitable society through a relationship with the Fair Wage Network (FWN) to understand living wages for the company's 3,800 global employees. Following a rigorous and thorough process where compensation data for all employees was reviewed on an anonymous basis and steps were taken to remediate any pay gaps, Ashland achieved certification as a Global Living Wage Employer .
- 06/18/2024
|
Ashland (ASH) Up 4% Since Last Earnings Report: Can It Continue?
- Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
- 05/30/2024
|
13 Upcoming Dividend Increases
- Thirteen dividend increases are featured, with RLI Corp leading the charge with a 49-year streak and a potential to become a dividend king next year. The list is created by merging data from the "U.S. Dividend Champions" spreadsheet and upcoming dividend data from NASDAQ. The article provides additional metrics, tickers by yield and growth rates, and historical returns for investors to consider before making investment decisions.
- 05/27/2024
|
3 Future Breakout Stocks That Wall Street Is Already Loving
- Investors looking for breakout stocks to buy that Wall Street already loves should find it easier now that the S&P 500 is near 52-week and all-time highs. The index is up nearly 12% year to date thanks to an almost 5% gain in the past month.
- 05/17/2024
|
Ashland (ASH) to Divest Nutraceuticals Business to Turnspire
- Ashland (ASH) is set to sell its nutraceuticals business to Turnspire Capital Partners, with the deal expected to close in third-quarter 2024.
- 05/09/2024
|
Ashland Board appoints Ashish K. Kulkarni as new director
- WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors. Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization. He is the former executive vice president and chief innovation officer, GAF, former chief technology and innovation officer, Avantor and former chief technology and innovation officer, Celanese Corporation. He will serve on the Board's Environmental, Health, Safety and Quality, and Compensation Committees, effective May 6, 2024. Prior to Celanese, Kulkarni held leadership positions at United Technologies Corporation, American Standard and General Electric.
- 05/08/2024
|
Ashland (ASH) is a Top-Ranked Momentum Stock: Should You Buy?
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 05/08/2024
|
Ashland board authorizes quarterly dividend
- WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock which represents a five percent increase from the previous quarter. The dividend is payable on June 15, 2024, to stockholders of record at the close of business on June 1, 2024.
- 05/07/2024
|
Turnspire Capital Partners to Acquire Ashland Nutraceuticals Business
- NEW YORK--(BUSINESS WIRE)--Turnspire Capital Partners LLC (“Turnspire”) announced today that an affiliate has signed a definitive agreement to acquire the nutraceuticals business of Ashland Inc. (NYSE: ASH) (“Ashland Nutraceuticals” or the “Business”). Ashland Nutraceuticals is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Business also.
- 05/07/2024
|
Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners
- WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC (“Turnspire”). The transaction is expected to close in the calendar third quarter 2024, subject to the satisfaction of customary closing conditions.
- 05/07/2024
|
Is Ashland Inc. (ASH) Stock Outpacing Its Basic Materials Peers This Year?
- Here is how Ashland (ASH) and Buenaventura (BVN) have performed compared to their sector so far this year.
- 05/06/2024
|
Ashland's (ASH) Earnings & Revenues Surpass Estimates in Q2
- Softer pricing hurts Ashland (ASH) sales for the fiscal second quarter.
- 05/02/2024
|
Why Ashland Stock Fell Today
- Ashland beat on earnings but forecasted continued revenue sluggishness. The company sees some key end markets recovering and is lessening its reliance on some more cyclical products.
- 05/01/2024
|
Ashland (ASH) Reports Q2 Earnings: What Key Metrics Have to Say
- The headline numbers for Ashland (ASH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 04/30/2024
|
Ashland (ASH) Tops Q2 Earnings and Revenue Estimates
- Ashland (ASH) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.43 per share a year ago.
- 04/30/2024
|
Ashland reports financial results1 for second quarter fiscal 2024; issues outlook for third quarter and full-year fiscal 2024
- WILMINGTON, Del., April 30, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the second quarter of fiscal year 2024, which ended March 31, 2024, and issued its outlook for third quarter and full-year fiscal 2024. The global additives and specialty ingredients company holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.
- 04/30/2024
|
Ashland sets date for fiscal 2024 second-quarter earnings release and conference call webcast
- WILMINGTON, Del., April 18, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its second-quarter earnings release at approximately 5 p.m. ET on Tuesday, April 30, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, May 1. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com .
- 04/18/2024
|
Ashland Board appoints Scott A. Tozier as new director
- Tozier is strategic advisor to the CEO, and former executive vice president and chief financial officer of Albemarle Corporation Tozier is strategic advisor to the CEO, and former executive vice president and chief financial officer of Albemarle Corporation
- 04/15/2024
|
Ashland announces executive organization changes to personal care and specialty additives
- WILMINGTON, Del. , April 03, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), the global additives and specialty ingredients company today announced executive organization changes to its personal care and specialty additives businesses.
- 04/03/2024
|
Why Is Ashland (ASH) Up 0.2% Since Last Earnings Report?
- Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
- 02/29/2024
|
Can Ashland (ASH) Run Higher on Rising Earnings Estimates?
- Ashland (ASH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 02/06/2024
|
3 chemical stocks to play the industry breakout
- I hope you're the type of investor who will sit down and do the homework required to come out as a winner in the financial markets. When you do, you'll notice that the big guys at places like The Goldman Sachs Group NYSE: GS and other respectable investment houses generate their ideas through a process called 'top-down' research.
- 02/06/2024
|
Why Ashland Stock Popped Today
- Ashland easily beat earnings estimates to start its new fiscal year. The specialty materials company also issued strong forward revenue guidance, citing improving demand trends.
- 01/31/2024
|
Ashland Inc. (ASH) Q1 2024 Earnings Call Transcript
- Ashland Inc. (ASH) Q1 2024 Earnings Call Transcript
- 01/31/2024
|
Ashland's (ASH) Q1 Earnings Beat Estimates, Revenues Miss
- Ashland's (ASH) first-quarter earnings top estimates while sales lag on volume weakness.
- 01/31/2024
|
Ashland (ASH) Reports Q1 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 01/30/2024
|
Ashland (ASH) Q1 Earnings Surpass Estimates
- Ashland (ASH) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.97 per share a year ago.
- 01/30/2024
|
Ashland sets date for fiscal 2024 first-quarter earnings release and conference call webcast
- WILMINGTON, Del., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter earnings release at approximately 5 p.m. ET on Tuesday, January 30, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, January 31, 2024. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com .
- 01/16/2024
|
Why Is Ashland (ASH) Up 14.7% Since Last Earnings Report?
- Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
- 12/08/2023
|
Ashland's (ASH) Q4 Earnings Miss Estimates, Revenues Meet
- Sales of Ashland (ASH) are adversely impacted by lower volumes from customer inventory destocking, partly offset by favorable pricing in Q4.
- 11/09/2023
|
Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say
- The headline numbers for Ashland (ASH) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 11/08/2023
|
Ashland provides update on fiscal 2023 fourth-quarter and full-year earnings1 and announces upcoming portfolio-optimization actions; sets date for fiscal 2023 fourth-quarter earnings release
- WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today provided an update for preliminary fiscal 2023 fourth-quarter results, full-year sales and Adjusted EBITDA.1 Ashland's financial results during the quarter reflect market-demand dynamics and underlying business performance that were generally consistent with previously communicated expectations. Earnings for the quarter were most directly impacted by additional inventory-reduction actions taken to better position the company for more conservative demand scenarios.
- 11/01/2023
|
4 Chemical Stocks Set to Pull Off a Beat This Earnings Season
- While softer demand in certain end markets is likely to be a drag, LyondellBasell (LYB), Chemours (CC), Axalta Coating Systems (AXTA) and Ashland (ASH) are likely to have benefited from cost and pricing actions.
- 10/25/2023
|
New Strong Sell Stocks for September 26th
- ALPMY, ASH and DHC have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2023.
- 09/26/2023
|
This Analyst With Over 80% Accuracy Rate Sees Around 9% Upside In Smucker - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
- U.S. stocks closed lower on Friday, ahead of the Federal Reserve's policy meeting this week. The Dow, meanwhile, settled slightly higher last week, while the S&P 500 and Nasdaq both recorded losses for the second straight week.
- 09/18/2023
|
New Strong Sell Stocks for August 24th
- AFCG, ASH and BHLB have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2023.
- 08/24/2023
|
New Strong Sell Stocks for August 16th
- ASH, CBRE and CMTG have been added to the Zacks Rank #5 (Strong Sell) List on August 16, 2023.
- 08/16/2023
|
New Strong Sell Stocks for August 8th
- ASH, BASFY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 8, 2023.
- 08/08/2023
|
Ashland (ASH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 07/25/2023
|
Ashland (ASH) Lags Q3 Earnings and Revenue Estimates
- Ashland (ASH) came out with quarterly earnings of $1.23 per share, missing the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $1.89 per share a year ago.
- 07/25/2023
|
New Strong Sell Stocks for July 25th
- ASH, CTS and CP have been added to the Zacks Rank #5 (Strong Sell) List on July 25, 2023.
- 07/25/2023
|
New Strong Sell Stocks for July 19th
- ASH, BASFY and BGC have been added to the Zacks Rank #5 (Strong Sell) List on July 19, 2023.
- 07/19/2023
|
Ashland sets date for fiscal 2023 third-quarter earnings release and conference call webcast
- WILMINGTON, Del., July 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fiscal-third quarter earnings release at approximately 5 p.m. ET on Tuesday, July 25, 2023. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, July 26, 2023. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com .
- 07/14/2023
|
New Strong Sell Stocks for July 11th
- APELY, ASH and BASEY have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2023.
- 07/11/2023
|
Ashland (ASH) Provides Key Updates on Q3 and FY23 Outlook
- Ashland (ASH) faces challenges stemming from customer de-stocking and macroeconomic uncertainties, as reflected in its Q3 preliminary results and updated outlook for fiscal year 2023.
- 06/29/2023
|
Ashland Stock: A Tougher 2023
- Ashland Inc. has seen a softer start to 2023. The company's performance has been rather stable in the first half of the year, while growth was anticipated. Investors have priced in these setbacks, with valuations coming down amidst lower expectations.
- 06/23/2023
|
Is the Options Market Predicting a Spike in Ashland (ASH) Stock?
- Investors need to pay close attention to Ashland (ASH) stock based on the movements in the options market lately.
- 06/14/2023
|
Why Is Ashland (ASH) Down 6% Since Last Earnings Report?
- Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
- 06/01/2023
|
Ashland: Strong Performance Despite Macroeconomic Headwinds
- Sales are stabilizing after a long restructuring process, but demand remains weak as customers hold high inventories. Profit margins have increased significantly in recent years thanks to the divestment of less profitable businesses.
- 05/28/2023
|
Ashland (ASH) Raises Dividend, Announces Share Buyback Plan
- Ashland's (ASH) goal is to have an annual dividend payout ratio of about 30% of adjusted income from continuing operations.
- 05/17/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of May 14
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 05/13/2023
|
Ashland's (ASH) Earnings and Revenues Lag Estimates in Q2
- Demand weakness in personal care and specialty additives and customer inventory destocking hurt Ashland's (ASH) Q2 results.
- 05/05/2023
|
Ashland (ASH) Misses Q2 Earnings and Revenue Estimates
- Ashland (ASH) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.50 per share a year ago.
- 05/02/2023
|
Ashland sets date for fiscal 2023 second-quarter earnings release and conference call webcast
- WILMINGTON, Del., April 20, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its second-quarter earnings release at approximately 5 p.m. ET on Tuesday, May 2, 2023. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, May 3, 2023. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com .
- 04/20/2023
|
Why You Should Add Ashland (ASH) Stock to Your Portfolio
- Ashland (ASH) gains on strong demand in its consumer end markets and its pricing actions to counter inflation.
- 03/30/2023
|
Here's Why You Should Retain Ashland (ASH) Stock for Now
- Ashland (ASH) benefits from healthy demand in most consumer end markets, the Schulke & Mayr acquisition and its pricing and mix improvement actions to counter inflation.
- 03/24/2023
|
Ashland (ASH) Gains on Pharma Business Strength & Pricing
- Ashland (ASH) benefits from strength in its global pharma business, the Schulke & Mayr acquisition and its pricing and mix improvement actions to counter inflation.
- 03/13/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of March 12
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 03/11/2023
|
Why Is Ashland (ASH) Down 5.4% Since Last Earnings Report?
- Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
- 03/02/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of February 26
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 02/26/2023
|
Ashland: Risen From The Ashes
- Ashland, Inc. has seen a great transformation over the past couple of years. The company has moved from a cyclical and leveraged business to a simpler and higher-margin specialty business.
- 02/23/2023
|
Ashland Inc. (ASH) Q1 2023 Earnings Call Transcript
- Ashland Inc. (NYSE:ASH ) Q1 2023 Earnings Conference Call February 1, 2022 9:00 AM ET Company Participants Seth Mrozek - Director, IR Guillermo Novo - Chairman & CEO Kevin Willis - SVP & CFO Conference Call Participants Christopher Parkinson - Mizuho Securities Joshua Spector - UBS David Begleiter - Deutsche Bank John McNulty - BMO Capital Markets Mike Harrison - Seaport Research Partners John Roberts - Credit Suisse Jeffrey Zekauskas - JPMorgan Michael Sison - Wells Fargo Laurence Alexander - Jefferies Operator Good day, and thank you for standing by. Welcome to the Ashland Inc. First Quarter 2023 Earnings Conference Call.
- 02/01/2023
|
Ashland (ASH) Tops Q1 Earnings Estimates
- Ashland (ASH) delivered earnings and revenue surprises of 2.11% and 0.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 01/31/2023
|
Ashland provides update on fiscal 2023 first-quarter earnings and maintains its financial outlook for fiscal year 2023; sets date for fiscal 2023 first-quarter earnings release
- WILMINGTON, Del., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today provided an update for preliminary fiscal 2023 first-quarter financial results1 and maintained its outlook for fiscal year 2023 results. Additional information regarding first-quarter fiscal 2023 earnings and full-year outlook will be shared during a conference call webcast with securities analysts on Wednesday, February 1, 2023.
- 01/25/2023
|
Why Ashland (ASH) Could Beat Earnings Estimates Again
- Ashland (ASH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/19/2023
|
Ashland (ASH) Up 13% in 3 Months: What's Driving the Stock?
- Ashland (ASH) gains on strong demand in most consumer end markets and its pricing and mix improvement actions.
- 01/19/2023
|
Here's Why You Should Hold Onto Ashland (ASH) Stock for Now
- Ashland (ASH) gains on solid demand in most consumer end markets, the Schulke & Mayr acquisition and its pricing and mix improvement actions to counter inflation.
- 12/21/2022
|
METAFORA partner Wugen to Present Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology's (ASH) 64th Annual Meeting
- PARIS, France & NEW ORLEANS, La.--( BUSINESS WIRE )--METAFORA biosystems announces that its partner Wugen presented data supporting clinical development of WU-NK-101 yesterday for relapsed / refractory AML at the American Society of Hematology's (ASH) 64th Annual Meeting. Metafora worked with the Wugen team to characterize Wugen's drug candidate WU-NK-01, a novel, off-the-shelf therapy for AML, which Wugen expects to advance to the clinic.
- 12/12/2022
|
Ashland (ASH) Shares Up 11% in 6 Months: What's Driving It?
- Ashland (ASH) benefits from strong demand in its end markets and its pricing actions to counter inflation.
- 12/12/2022
|
Ashland (ASH) Benefits From Strong End-Mmarket Demand & Pricing
- Ashland (ASH) gains on strong demand in its consumer end markets and its pricing actions to counter inflation.
- 12/06/2022
|
4 Chemical Specialty Stocks to Escape Industry Challenges
- Slowing end-market demand and input cost pressure dampen prospects for the Zacks Chemicals Specialty industry. ASH, LTHM, NGVT and FSI are set to gain from self-help actions.
- 11/23/2022
|
What Makes Ashland (ASH) a Strong Momentum Stock: Buy Now?
- Does Ashland (ASH) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 11/14/2022
|
Ashland's (ASH) Earnings Beat Estimates in Q4, Revenues Lag
- Ashland (ASH) gains on disciplined pricing actions, strong demand and better product mix in Q4.
- 11/11/2022
|
Lithium Leader Breaks Out As EV Demand Fuels 614% Growth
- As demand for EVs like Tesla continues, lithium leader Albemarle delivers huge growth. ALB stock is now charging a new breakout.
- 11/09/2022
|
Ashland Inc. (ASH) Q4 2022 Earnings Call Transcript
- Ashland Inc. (NYSE:ASH ) Q4 2022 Earnings Conference Call November 8, 2022 9:00 AM ET Company Participants Seth Mrozek - Director, Investor Relations Guillermo Novo - Chairman and Chief Executive Officer John Kevin Willis - Senior Vice President and Chief Financial Officer Conference Call Participants Christopher Parkinson - Mizuho Securities David Begleiter - Deutsche Bank Lucas Beaumont - UBS Mike Harrison - Seaport Research Partners John McNulty - BMO Capital Markets Laurence Alexander - Jefferies Edlain Rodriguez - Credit Suisse Operator Good day. And thank you for standing by.
- 11/08/2022
|
Ashland (ASH) Surpasses Q4 Earnings Estimates
- Ashland (ASH) delivered earnings and revenue surprises of 5.04% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/07/2022
|
Why You Should Add Ashland (ASH) Stock to Your Portfolio
- Ashland (ASH) gains on strong demand in its consumer end markets and its pricing actions to counter inflation.
- 09/14/2022
|
Ashland (ASH) Shares Up 17% in 6 Months: What's Driving It?
- Ashland (ASH) benefits from strong demand in its end markets and its pricing actions to counter inflation.
- 08/30/2022
|
Ashland: A Case Study In Conglomerate Revitalization
- The story of Ashland is one of a conglomerate shedding waste. While Ashland's financial data may suggest weak performance over a longer timeframe, the past four quarters may highlight a new trend.
- 08/22/2022
|
Will Ashland (ASH) Gain on Rising Earnings Estimates?
- Ashland (ASH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 08/16/2022
|
Ashland (ASH) Tops Q3 Earnings and Revenue Estimates
- Ashland (ASH) delivered earnings and revenue surprises of 0.53% and 0.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/26/2022
|
Ashland (ASH) Issues Fiscal Q3 Update, Raises FY22 Outlook
- Ashland (ASH) projects adjusted earnings from continuing operations for the fiscal third quarter of roughly $104 million or $1.89 per share.
- 07/19/2022
|
Ashland (ASH) Earnings Expected to Grow: Should You Buy?
- Ashland (ASH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/19/2022
|
Ashland provides update on fiscal 2022 third-quarter earnings and raises its financial outlook for fiscal year 2022; sets date for fiscal 2022 third-quarter earnings release
- WILMINGTON, Del., July 18, 2022 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today provided an update for preliminary fiscal 2022 third-quarter financial results1 and raised its outlook for fiscal year 2022 results. Additional information regarding third-quarter fiscal 2022 earnings and full-year outlook will be shared during a conference call webcast with securities analysts on Wednesday, July 27, 2022.
- 07/18/2022
|
Can Ashland (ASH) Keep the Earnings Surprise Streak Alive?
- Ashland (ASH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/08/2022
|
What Makes Ashland (ASH) Stock a Solid Choice Right Now
- Ashland (ASH) benefits from strong demand in most consumer end markets and its pricing actions to counter inflation.
- 07/08/2022
|
Ashland (ASH) Benefits From Strong End-Market Demand & Pricing
- Ashland (ASH) gains on solid demand in most consumer end markets and its pricing and mix improvement actions to counter cost inflation.
- 06/22/2022
|
Here's Why You Should Add Ashland (ASH) Stock to Your Portfolio
- Ashland (ASH) gains on strong demand and its pricing and mix improvement actions to counter inflation.
- 06/09/2022
|
Strong Start Fades; JinkoSolar, Ashland, And Atkore Buy Points Have Caveats | Stock Market Today
- These stocks represent strengthening industry groups. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
- 06/06/2022
|
Ashland (ASH) Hikes Dividend by 12%, Declares $500M Buyback
- Ashland (ASH) announces a quarterly cash dividend of 33.5 cents per share on its common stock.
- 05/26/2022
|
5 Analyst Favorite Blue Chip Stocks to Buy With Dividend Hikes Likely This Week
- After years of a low interest rate environment, which now is trending higher, many investors have turned to equities, not only for the growth potential but also for the solid and dependable dividends that help to provide an income stream.
- 05/23/2022
|
Ashland (ASH) Just Overtook the 20-Day Moving Average
- Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
- 05/04/2022
|
Ashland Global Holdings Inc (ASH) CEO Guillermo Novo on Q2 2022 - Earnings Call Transcript
- Ashland Global Holdings Inc (NYSE:ASH ) Q2 2022 Earnings Conference Call April 27, 2022 9:00 AM ET Company Participants Guillermo Novo – Chairman and Chief Executive Officer John Kevin Willis – Senior Vice President and Chief Financial Officer Seth Mrozek – Director of Investor Relations Conference Call Participants John McNulty – Bank of Montreal Capital Markets Christopher Parkinson – Mizuho Josh Spector – Union Bank of Switzerland David Begleiter – Deutsche Bank Laurence Alexander – Jefferies Michael Sison – Wells Fargo Michael Harrison – Seaport Research Jeff Zekauskas – JPMorgan Operator Hello. Thank you for standing by and welcome to Ashland Inc Second Quarter 2022 Earnings Conference Call.
- 04/27/2022
|
Ashland's (ASH) Earnings and Revenues Surpass Estimates in Q2
- Ashland (ASH) benefits from strong demand across its end markets, disciplined pricing and better product mix in Q2.
- 04/27/2022
|
Buy 5 Mid-Cap Stocks Ahead of Earnings Results Next Week
- Five mid-cap companies will report earnings results next week. These are: PCH, RRC, MTDR, ASH, HP.
- 04/22/2022
|
Ashland (ASH) is a Great Momentum Stock: Should You Buy?
- Does Ashland (ASH) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 04/20/2022
|
Ashland (ASH) Updates Q2 Earnings and Affirms FY22 Outlook
- Ashland (ASH) anticipates net income to be around $786 million for Q2 driven by strong end-market demand, enhanced pricing and improved product mix.
- 04/18/2022
|
Ashland (ASH) to Hike Price upto 15% to Cover Higher Costs
- Ashland's (ASH) price hike includes all Ashland products across all the markets and applications the company serves.
- 03/22/2022
|
Ashland (ASH) Launches Nutrapress Organic Chewable Base
- Ashland (ASH) creates the organic chewable base with patent-pending technology.
- 03/15/2022
|
Ashland (ASH) Rolls Out ISO 10993 Compliant PSA Platform
- Ashland's (ASH) recently-launched product portfolio consists of seven highly competitive Aroset and Flexcryl acrylic PSAs developed for challenging applications.
- 02/10/2022
|
Ashland Global Holdings Inc. (ASH) CEO Guillermo Novo on Q1 2022 Results - Earning Call Transcript
- Ashland Global Holdings Inc. (ASH) CEO Guillermo Novo on Q1 2022 Results - Earning Call Transcript
- 02/02/2022
|
Ashland's (ASH) Earnings Beat Estimates in Q1, Revenues Lag
- Ashland (ASH) gains on strong demand in core global end markets, higher pricing and contributions from the Schulke & Mayr acquisition in Q1.
- 02/02/2022
|
Ashland (ASH) Q1 Earnings Top Estimates
- Ashland (ASH) delivered earnings and revenue surprises of 1.15% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/01/2022
|
Ashland (ASH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/25/2022
|
Ashland (ASH) Issues Updates on Q1 Earnings, Retains FY22 View
- Ashland (ASH) projects income from continuing operations for the fiscal first quarter of roughly $32 million or 55 cents per share.
- 01/19/2022
|
Ashland provides update on fiscal 2022 first-quarter earnings and maintains financial outlook for fiscal year 2022; sets date for fiscal 2022 first-quarter earnings release
- WILMINGTON, Del., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today provided an update for preliminary fiscal 2022 first-quarter financial results and maintained its outlook for fiscal year 2022 results. Additional information regarding first-quarter fiscal 2022 earnings will be shared during a conference call webcast with securities analysts on Wednesday February 2, 2022.
- 01/18/2022
|
Bear of the Day: Ashland Global (ASH)
- Should investors cash out of this winner near all-time highs?
- 01/14/2022
|
New Strong Sell Stocks for January 12th
- ASH, CAH, and ESTA have been added to the Zacks Rank #5 (Strong Sell) List on January 12, 2022
- 01/12/2022
|
Ashland (ASH) to Hike Prices of 1,4-Butanediol & Derivatives
- Ashland (ASH) is increasing the price of 1,4 butanediol by 45 cents per pound.
- 12/01/2021
|
Ashland Global Holdings, Inc. (ASH) CEO Guillermo Novo on Q4 2021 Results - Earnings Call Transcript
- Ashland Global Holdings, Inc. (ASH) CEO Guillermo Novo on Q4 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Ashland's (ASH) Earnings and Revenues Lag Estimates in Q4
- Ashland (ASH) Q4 performance benefits from strong demand in core markers and higher prices, despite headwinds from global supply-chain and logistics disruptions.
- 11/10/2021
|
Ashland (ASH) Misses Q4 Earnings and Revenue Estimates
- Ashland (ASH) delivered earnings and revenue surprises of -4.69% and -0.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2021
|
7 Stocks to Buy That Investors Should Keep ‘Holding' for Years to Come
- When you're looking for stocks to buy that you can hold for years to come, what's in a name is sometimes all you need to find your way. The post 7 Stocks to Buy That Investors Should Keep ‘Holding' for Years to Come appeared first on InvestorPlace.
- 10/21/2021
|
Ashland (ASH) Lowers FY'21 EBITDA View on Logistics Woes
- Ashland (ASH) modifies its previously communicated fiscal 2021 guidance, owing to cost and shipping challenges.
- 10/01/2021
|
New Strong Sell Stocks for September 30th
- ASH, BVN, LANC, MCB, and VRT have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2021.
- 09/30/2021
|
Ashland provides update on its outlook for fiscal 2021 financial results1
- WILMINGTON, Del., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today provided an update for preliminary fiscal 2021 financial results. In general, economic recovery in the U.S. and other regions of the world is driving strong demand for most products in the company's Life Sciences, Personal Care and Household, Specialty Additives and Performance Adhesives end markets.
- 09/27/2021
|
Ashland (ASH) to Hike Prices of 1,4-Butanediol & Derivatives
- Ashland (ASH) is increasing the price of 1,4 butanediol by 14 cents per pound.
- 09/15/2021
|
Ashland (ASH) Announces $450 Million Share Buyback Program
- Ashland (ASH) enters into an agreement with JP Morgan Chase to repurchase a total of $450 million of its common stock.
- 09/06/2021
|
Ashland announces $450 million accelerated share repurchase program
- WILMINGTON, Del,, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings, Inc. (NYSE: ASH) today announced that it has entered into an uncollared accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association, to repurchase an aggregate of $450 million of Ashland common stock, with an initial delivery of approximately 3.9 million shares. The program is subject to the $1 billion share repurchase program authorized by Ashland Board of Directors on March 15, 2018 from which $800 million is outstanding.
- 09/03/2021
|
Ashland signs definitive agreement to sell performance adhesives business to Arkema for $1.65 billion
- Upon completion of the sale, Ashland will be a focused additive and ingredients company with leadership positions in life sciences, personal care and coatings Upon completion of the sale, Ashland will be a focused additive and ingredients company with leadership positions in life sciences, personal care and coatings
- 08/31/2021
|
Ashland (ASH) Up 2.5% Since Last Earnings Report: Can It Continue?
- Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
- 08/26/2021
|
Ashland (ASH) Wraps Up Senior Notes Offering of $450 Million
- Ashland (ASH) plans to utilize net proceeds of the offering to redeem obligations under its outstanding 4.75% senior notes due 2022, post deducting initial purchasers' discounts, fees and expenses.
- 08/19/2021
|
Ashland Global Holdings Inc. announces completion of senior notes offering by Ashland LLC
- WILMINGTON, Del., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) announced today that its indirect, wholly owned subsidiary, Ashland LLC, has closed its previously announced offering of $450 million aggregate principal amount of 3.375 percent senior notes due 2031 (the “Notes”).
- 08/18/2021
|
Ashland Global Remains On The Right Track To Post A Strong Free Cash Flow Result
- Ashland Global sees its performance accelerate and the company posts a good income and free cash flow result. The full-year guidance implies Q4 will have the highest EBITDA of the entire year.
- 08/18/2021
|
Ashland (ASH) Prices Senior Notes Offering of $450 Million
- Ashland (ASH) plans to utilize net proceeds of the offering to redeem obligations under its outstanding 4.75% senior notes due 2022, post deducting initial purchasers' discounts, fees and expenses.
- 08/13/2021
|
EcoSynthetix Hits Key Milestones With Its Disruptive Biopolymers
- EcoSynthetix Hits Key Milestones With Its Disruptive Biopolymers
- 08/11/2021
|
Ashland Global Holdings Inc. announces pricing of senior notes offering by Ashland LLC
- WILMINGTON, Del., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced the pricing of an offering by its indirect, wholly owned subsidiary, Ashland LLC, of $450 million aggregate principal amount of 3.375 percent senior notes due 2031 (the “Notes”).
- 08/03/2021
|
Ashland Global Holdings Inc. announces offering of senior notes by Ashland LLC
- WILMINGTON, Del., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced the intention of its indirect, wholly owned subsidiary Ashland LLC to offer $450 million aggregate principal amount of senior notes (the “Notes”). The Notes will be senior unsecured obligations of Ashland LLC.
- 08/03/2021
|
Ashland's (ASH) Q3 Earnings Miss Estimates, Revenues Beat
- Ashland's (ASH) Q3 results were driven by resilient demand in core products, additional sales from recent acquisitions offset by supply-chain disruptions and a rise in raw-material costs.
- 07/28/2021
|
Ashland Global Holdings (ASH) CEO Guillermo Novo on Q3 2021 Results - Earnings Call Transcript
- Ashland Global Holdings (ASH) CEO Guillermo Novo on Q3 2021 Results - Earnings Call Transcript
- 07/28/2021
|
Ashland (ASH) Misses Q3 Earnings Estimates
- Ashland (ASH) delivered earnings and revenue surprises of -3.94% and 0.18%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/27/2021
|
Recap: Ashland Global Holdings Q3 Earnings
- Shares of Ashland Global Holdings (NYSE:ASH) increased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 45.24% over the past year to $1.22, which missed the estimate of $1.29.
- 07/27/2021
|
Ashland reports preliminary financial results1 for third quarter of fiscal year 2021
- WILMINGTON, Del., July 27, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced preliminary1 financial results for the third quarter of fiscal year 2021, which ended June 30, 2021. The global specialty materials company serves customers in a wide range of consumer and industrial markets.
- 07/27/2021
|
Earnings Preview For Ashland Global Holdings
- On Tuesday, July 27, Ashland Global Holdings (NYSE:ASH) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
- 07/26/2021
|
Ashland (ASH) to Report Q3 Results: Wall Street Expects Earnings Growth
- Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/20/2021
|
Ashland to report financial results for third quarter fiscal 2021 after NYSE closes July 27, and host webcast with securities analysts and investors at 9 a.m. ET July 28
- WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) will issue its third-quarter earnings release at approximately 5 p.m. ET on Tuesday, July 27, 2021. The company's live webcast with securities analysts and investors will take place at 9 a.m. ET, Wednesday, July 28, 2021 and include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website http://investor.ashland.com .
- 07/19/2021
|
Ashland (ASH) to Hike Prices for PSA Products in North America
- Ashland (ASH) will hike prices between 7 cents/lb and 10 cents/lb. as well as include Arocure, Aroset and Flexcryl product lines.
- 07/06/2021
|
Ashland (ASH) Issues Updates on Outlook for Q3 and Fiscal 2021
- Ashland (ASH) expects $5-$10 million of adjusted EBITDA pressure in fiscal third quarter.
- 06/11/2021
|
Ashland provides update on outlook for fiscal 2021 third-quarter and full-year earnings¹
- WILMINGTON, Del., June 10, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today provided an update for preliminary fiscal 2021 third-quarter and full-year financial results. In general, economic recovery in the U.S. and other regions of the world is driving strong demand for most products in the company's Life Sciences, Personal Care and Household and Specialty Additives end markets.
- 06/10/2021
|
Ashland (ASH) Launches Synthetic Thickeners for Waterborne Paints
- Ashland (ASH) introduces new synthetic thickeners that feature light shipments and zero residual waste and will go a long way in positively impacting the environment by reducing greenhouse emissions.
- 06/09/2021
|
Ashland Specialties signs Memorandum of Understanding with Dockwater BV
- ANTWERP, Belgium, June 8, 2021 /PRNewswire/ -- AVAIO Capital is pleased to announce that Ashland Specialties Belgium BVBA ("Ashland") has entered into a memorandum of understanding with Dockwater BV, to procure sustainable process water from the Dockwater project in the Port of Antwerp. Ashland joins the growing group of launch customers for Dockwater.
- 06/08/2021
|
Ashland (ASH) to Review Performance Adhesives Business Unit
- Ashland (ASH) intends to assess all options with respect to the Performance Adhesives business unit, including a potential divestment.
- 06/01/2021
|
Ashland announces strategic review of its performance adhesives business unit and enhanced focus on growth in high-value ingredients portfolio
- WILMINGTON, Del., May 25, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH), today announced a strategic review of its performance adhesives business unit. Ashland intends to evaluate all options with respect to the business unit, including a potential sale. The decision is consistent with the company's strategy to grow its integrated additive ingredients portfolio focused on its leadership positions in its core pharma, personal care, and coatings businesses.
- 05/25/2021
|
Ashland's (ASH) Coating Lab in Singapore to Support Local Needs
- Ashland (ASH) invests in a new architectural coating service laboratory in Singapore to bolster customer support in South East Asia and expand operations.
- 05/24/2021
|
Ashland board authorizes nine percent increase in quarterly dividend
- WILMINGTON, Del., May 20, 2021 (GLOBE NEWSWIRE) -- The board of directors of Ashland Global Holdings Inc. (NYSE: ASH) has authorized a nine percent increase in the quarterly dividend from $0.275 to $0.30 per share on the company's common stock.
- 05/20/2021
|
Ashland Global: Improved Performance In The First Semester, Pursuing M&A
- Ashland Global's performance is ramping up as the free cash flow increases. The net debt/EBITDA ratio would have been close to dropping to 2 by the end of this year, but Ashland decided to pursue M&A.
- 05/11/2021
|
Ashland Global Holdings Inc. (ASH) CEO Guillermo Novo on Q2 2021 Results - Earnings Call Transcript
- Ashland Global Holdings Inc. (ASH) CEO Guillermo Novo on Q2 2021 Results - Earnings Call Transcript
- 04/30/2021
|
Ashland completes acquisition of personal care business of Schülke & Mayr GmbH, a portfolio company of EQT
- WILMINGTON, Del., April 30, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced that it has completed the acquisition of the personal care business from Schülke & Mayr GmbH, a portfolio company of the global investment organization EQT.
- 04/30/2021
|
Ashland reports preliminary financial results1 for second quarter of fiscal year 2021
- WILMINGTON, Del., April 28, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced preliminary1 financial results for the second quarter of fiscal year 2021, which ended March 31, 2021. The global specialty materials company serves customers in a wide range of consumer and industrial markets.
- 04/28/2021
|
Ashland to report financial results for second quarter fiscal 2021 after NYSE closes April 28, and host webcast with securities analysts and investors at 10 a.m. ET April 29
- WILMINGTON, Del., April 23, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) will issue its second-quarter earnings release at approximately 5 p.m. ET on Wednesday, April 28, 2021. The company's live webcast with securities analysts and investors will take place at 10 a.m. ET, Thursday, April 29, 2021 and include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website http://investor.ashland.com .
- 04/23/2021
|
Ashland furthers ESG agenda on Earth Day and supports The Nature Conservancy forest restoration effort to help Plant a Billion Trees
- Wilmington, Del., April 22, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced the company's commitment to support a collaborative forest restoration effort of The Nature Conservancy to help Plant a Billion Trees by 2030, advancing the broader development goals of the United Nations, specifically the Sustainable Development Goal for Life on Land.
- 04/22/2021
|
What Makes Ashland (ASH) Stock a Solid Choice Right Now
- Ashland (ASH) benefits from improving global industrial demand and cost-reduction measures.
- 04/07/2021
|
4 Chemical Specialty Stocks to Buy From a Rebounding Industry
- 4 Chemical Specialty Stocks to Buy From a Rebounding Industry
- 04/06/2021
|
5 Top Specialty Chemical Stocks to Snap Up on Demand Upturn
- An upturn in demand across major end-markets such as construction and automotive instills optimism in the specialty chemical space. DQ, ASH, ESI, CE and KRA are worth betting on right now.
- 04/01/2021
|
Ashland (ASH) to Expand Natrosol HEC Capacity at China Site
- Ashland's (ASH) capacity expansion signifies its commitment toward investing in Asia, which will enable it to meet the unprecedented demand of consumers.
- 03/23/2021
|
4 Specialty Chemicals Stocks to Gain From Industry Turnaround
- The global specialty chemicals industry seems poised to rebound on the gradual resumption of economic activities worldwide, making it prudent to invest in names like Kraton (KRA) and Hawkins (HWKN)
- 03/17/2021
|
Ashland to increase production capacity for Natrosol™ HEC at Nanjing, China site
- Wilmington, Del., March 15, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced the company plans to increase production capacity of Natrosol™ hydroxyethylcellulose (HEC) at the Nanjing, China site.
- 03/15/2021
|
Ashland (ASH) to Increase Prices for Adhesives Products
- Ashland's (ASH) price increase is in response of the continuous cost increase in feedstock, key raw materials and freight.
- 03/08/2021
|
Ashland (ASH) Down 1.1% Since Last Earnings Report: Can It Rebound?
- Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
- 03/05/2021
|
G.research to Host 12th Annual Specialty Chemicals Conference
- RYE, N.Y.--(BUSINESS WIRE)--G.research would like to invite you to the 12th Annual Specialty Chemicals Conference Thursday, March 11th. This timely conference will feature presentations by senior management of several leading Specialty Chemical companies, with an emphasis on industry dynamics, new technologies, and company fundamentals. Registration Link: https://www.research.gabellisecurities.com/conferences/4/register Presenting Companies: Ashland Global Holdings (NYSE: ASH) CMC Minerals (NAS
- 03/01/2021
|
Ashland (ASH) Upgraded to Buy: Here's What You Should Know
- Ashland (ASH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 02/09/2021
|
Ashland Global Holdings, Inc. (ASH) CEO Guillermo Novo on Q1 2021 Results - Earnings Call Transcript
- Ashland Global Holdings, Inc. (ASH) CEO Guillermo Novo on Q1 2021 Results - Earnings Call Transcript
- 02/04/2021
|
Ashland's (ASH) Earnings and Sales Surpass Estimates in Q1
- Ashland (ASH) benefits from strong overall demand and cost-reduction actions in the fiscal first quarter.
- 02/04/2021
|
Ashland (ASH) Q1 Earnings and Revenues Beat Estimates
- Ashland (ASH) delivered earnings and revenue surprises of 50.00% and 1.58%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/03/2021
|
Recap: Ashland Global Holdings Q1 Earnings
- Shares of Ashland Global Holdings (NYSE:ASH) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 623.08% over the past year to $0.94, which beat the estimate of $0.63.
- 02/03/2021
|
Ashland reports preliminary financial results for first quarter of fiscal year 2021
- WILMINGTON, Del., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced preliminary1 financial results for the first quarter of fiscal year 2021, which ended December 31, 2020. The global specialty materials company serves customers in a wide range of consumer and industrial markets.
- 02/03/2021
|
Ashland commits to Science Based Targets initiative and becomes signatory to the United Nations Global Compact furthering the company's ESG agenda
- Business plans include sustainability within innovation strategy, science-based emissions reduction targets and human rights, labor, environment and anti-corruption goals Business plans include sustainability within innovation strategy, science-based emissions reduction targets and human rights, labor, environment and anti-corruption goals
- 02/01/2021
|
Ashland board declares quarterly dividend
- WILMINGTON, Del., Jan. 29, 2021 (GLOBE NEWSWIRE) -- The board of directors of Ashland Global Holdings Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.275 per share on the company's common stock. The dividend is payable March 15, 2021, to stockholders of record at the close of business on February 26, 2021. As of December 31, 2020, there were 60,667,388 shares of Ashland common stock outstanding.
- 01/29/2021
|
Ashland to report financial results for first quarter fiscal 2021 after NYSE closes February 3, and host webcast with securities analysts and investors at 9 a.m. ET February 4
- WILMINGTON, Del., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) will issue its first-quarter earnings release at approximately 5 p.m. ET on February 3, 2021. The company's live webcast with securities analysts and investors will take place at 9 a.m. ET, Thursday, February 4, 2021 and include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website http://investor.ashland.com.
- 01/19/2021
|
Ashland to acquire personal care business of Schülke & Mayr GmbH, a portfolio company of EQT
- Transaction enhances Ashland's specialty additives position in personal care, expands biotechnology and microbiology technical competencies and advances ESG agenda Transaction enhances Ashland's specialty additives position in personal care, expands biotechnology and microbiology technical competencies and advances ESG agenda
- 01/19/2021
|
Wall Street Billionaire Leon Cooperman Warns Market Is ‘Not Going To End Well' – But He Still Likes These 5 Investments
- The hedge fund titan worries about the market's long-term outlook but is still betting on select securities.
- 01/12/2021
|
Ashland board declares quarterly dividend
- WILMINGTON, Del., Nov. 18, 2020 (GLOBE NEWSWIRE) -- The board of directors of Ashland Global Holdings Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.275 per share on the company's common stock. The dividend is payable December 15, 2020, to stockholders of record at the close of business on December 1, 2020. As of October 31, 2020, there were 60,578,546 shares of Ashland common stock outstanding.
- 11/18/2020
|
Ashland Global Holdings, Inc. (ASH) CEO Guillermo Novo on Q4 2020 Results - Earnings Call Transcript
- Ashland Global Holdings, Inc. (ASH) CEO Guillermo Novo on Q4 2020 Results - Earnings Call Transcript
- 11/11/2020
|
Ashland (ASH) Beats Q4 Earnings and Revenue Estimates
- Ashland (ASH) delivered earnings and revenue surprises of 25.32% and 4.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2020
|
Recap: Ashland Global Holdings Q4 Earnings
- Shares of Ashland Global Holdings (NYSE:ASH) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 62.34% over the past year to $1.25, which beat the estimate of $0.75.
- 11/10/2020
|
Ashland reports preliminary financial results for fourth quarter of fiscal year 2020
|
Earnings Preview for Ashland Global Holdings
- On Tuesday, November 10, Ashland Global Holdings (NYSE: ASH) will release its latest earnings report. Here is Benzinga's outlook for the company.
- 11/09/2020
|
Ashland to report financial results for fourth quarter of fiscal 2020 after NYSE closes November 10 and host webcast with securities analysts and investors at 9 a.m. ET November 11
- WILMINGTON, Del., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter earnings at approximately 5 p.m. ET on November 10, 2020. The company's live webcast with securities analysts and investors will take place at 9 a.m. ET on Wednesday, November 11, 2020 and include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com .
- 10/30/2020
|
New Aromatic Solvents Market Research Highlights Recovery Path for Businesses from COVID-19 based on Paints and Coatings, Automotive, and Pharmaceuticals End-Users | Technavio
- The Global Aromatic Solvents Market will grow by USD 1.09 bn during 2020-2024
- 09/14/2020
|
Dividend Champion And Contender Highlights: Week Of September 13
- A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends.
- 09/12/2020
|
Dividend Champions For September 2020
- Monthly update of the Dividend Champions List. 34 companies declared higher dividends in the past month, with an average increase of 8.4% over their previous payouts.
- 09/02/2020
|
Dividend Champion And Contender Highlights: Week Of August 23
- A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends.
- 08/22/2020
|
Leon Cooperman Abandons Alphabet in 2nd Quarter
- Multiple positions reduced in guru's portfolio Continue reading...
- 08/17/2020
|
Ashland board declares quarterly dividend
- WILMINGTON, Del., Aug. 12, 2020 (GLOBE NEWSWIRE) -- The board of directors of Ashland Global Holdings Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.275 per share on the company's common stock. The dividend is payable September 15, 2020, to stockholders of record at the close of business on September 1, 2020. As of July 31, 2020, there were 60,542,901 shares of Ashland common stock outstanding.About Ashland Ashland Global Holdings Inc. (NYSE: ASH) is a premier global specialty chemicals company serving customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. At Ashland, we are approximately 4,600 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – who thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com to learn more. ™ Trademark, Ashland or its subsidiaries, registered in various countries.Investor Relations:Media Relations: Seth A. MrozekCarolmarie Brown +1 (302) 594-5010+1 (302) 995-3158 samrozek@ashland.comccbrown@ashland.com Attachment * Ashland board announces quarterly dividend - Final 20200812
- 08/12/2020
|
Concrete Admixtures Market Highlights the Impact of COVID-19 (2020-2024) | Increasing Demand for Plasticizers to boost Market Growth | Technavio
- The Global Concrete Admixtures Market will grow by USD 3.54 bn during 2020-2024
- 08/11/2020
|
Analysts Say These 3 Stocks Are Their Top Picks for 2020 and Beyond
- The S&P 500 is just 1% away from its all-time high, and investors show no signs of stopping their buying spree. Low interest rates and heavy government stimulus are supporting the equity markets, making stocks a better value than other investments. As far as the stock markets can show, the economy is well on its way to recovery from the coronavirus downturn.And Credit Suisse, the renowned international investment bank and financial services provider, has been busy analyzing the publicly traded companies, looking for the likely winners in today’s conditions. The firm’s analysts have picked out three, among others, as ‘top pick’ stocks that are poised to outperform over the next 6 to 12 months.Opening up the TipRanks database, we’ve pulled the details on those stocks, to find out what makes so compelling. Here are the results.Cimarex Energy (XEC)We’ll start with Denver-based Cimarex, a hydrocarbon exploration company with drilling ops in New Mexico, Texas, and Oklahoma. The company finished 2019 with 620 million barrels of proven reserves, and an average daily production of 278.5 thousand barrels of oil equivalent. That was a solid foundation, which has helped support the company during the corona crisis of 1H20.The economic downturn of recent months hit Cimarex hard, as oil demand dropped. The company saw earnings contract in Q1, and contract again in Q2. Production in the second quarter averaged 254.7 thousand barrels of oil equivalent daily, well below 2019 levels.There was good news, however. The company generated $145 million in cash from operations, and invested $84 million during the quarter, with $49 million of that going into drilling and well completion. The company’s balance sheet is strong, with no borrowing against the revolving credit facility and while there is outstanding debt of $2 billion, the notes do not mature until 2024. Cimarex finished Q2 with a $44 million cash balance, and $26 million in free cash flow after funding the dividend.The dividend is another clear attraction for investors. The company has declared the current payment, due later this month, of 22 cents per common share – which is up from the end of last year. The yield, at 3.2%, is well above average.William Janela, 4-star analyst from Credit Suisse, wrote the firms review of XEC, and was impressed by those last points: the free cash flow, and the dividend. He said in his note, “XEC is our top pick among SMID-cap E&Ps given a defensive balance sheet (investment grade, fully undrawn $1.5 billion revolver, no debt maturities until 2024), a commitment/ability to fund both capex and an above-average dividend yield within cash flow, and attractive relative valuation.”To this end, Janela rates XEC an Outperform (i.e. Buy), along with a $39 price target. This figure suggests the stock has room for 33% upside growth from current levels. (To watch Janela’s track record, click here)Overall, Cimarex has a Moderate Buy rating from the analyst consensus, based on 12 Buys against 4 Holds. The stock’s current share price is $29.10, and the $37.08 average target implies an upside potential of 27%. (See Cimarex stock analysis on TipRanks)Bloom Energy (BE)A publicly traded company since 2018, Bloom Energy is a player in the green energy market. The company produces and sells solid oxide fuel cells, a cleaner alternative to petrofuels or traditional batteries.Bloom has seen strong results in the first half, despite the coronavirus. The company reported $187.9 million in Q2 revenues, along with 306 customer acceptances. That last metric represented a 19.5% sequential increase, and a surge in new business. Company shares spiked in July, getting well above pre-market crash levels, and even after an early August drop, BE shares remain high.The company announced on August 6 that it will be offering $135 million in senior convertible notes to be due in 2025. The new debt will be used to pay down a series of 10% promissory notes due next year, in effect converting short-term debt into long-term debt. The move is seen as a stabilizing factor for the company.5-star Credit Suisse’s Michael Weinstein sees a clear path for Bloom going forward. He writes, “We expect near-term shipment growth from strong demand for reliable power supply during wildfire peers. New opporand cold season, and continued demand from data centers/hospitals. Bloom Energy’s fuel cells operate on natural gas today and can take advantage of low-cost natural gas, unliketunities have emerged in the last month (fuel cells in ships, hydrogen powered fuel cells, and electrolyzer) that position Bloom Energy as a key manufacturer of building blocks in a hydrogen economy."Weinstein’s Buy rating is supported by his $24 price target, which implies a robust 87% one-year upside for the stock. (To watch Weinstein’s track record, click here)Overall, BE has a Moderate Buy from the analyst consensus, with 3 Buy ratings and 2 Holds. The average price target, $17.25, represents a 33% upside from the current share price of $12.97. (See Bloom stock analysis on TipRanks)Ashland (ASH)Last on our list today, Ashland, is a Kentucky-based specialty chemicals company, producing solvents, composites, and industrial specialties, as well as personal & home care products, pharmaceuticals, and agricultural chemicals. The company saw stable earnings in the first half, with revenues beating forecasts in Q2 despite a 6% year-over-year drop in sales.Ashland saw some positives on the balance sheet in its recent results. Cash on hand increased more than two-fold yoy to $353 million, while long-term debt fell 33%. The company generated $47 million in cash from operations, which was up $15 million from the year-ago quarter. All in all, the solid cash position has supported the company during the economic crisis.4-star analyst Chris Parkinson, writing the Credit Suisse view of Ashland, sees the company as a strong performer. He gives the stock a Buy rating, and his $91 price target indicates confidence – and a 15% upside potential for the stock. (To watch Parkinson’s track record, click here)Supporting his view, Parkinson writes, “ASH has shown it’s ability to quickly realign business functions from a vertical to horizontal structure which is driving mix improvement and will drive cost improvement / ROIC accountability (changes in comp structure will be supportive). ASH continues to execute on costcutting opportunities and improving FCF conversion will enable future investment opportunities.” All in all, Ashland has a Strong Buy from the analyst consensus, based on 9 reviews, including 7 Buys and 2 Holds. The stock is trading for $79.44, and the average price target, at $88.50, suggests about 11% upside. (See Ashland stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment
- 08/10/2020
|
Insights into the Global Polyurethane Adhesives Market to 2024 - Key Drivers, Challenges and Trends - ResearchAndMarkets.com
|
Brokers Set Expectations for Ashland Global Holdings Inc’s Q4 2020 Earnings (NYSE:ASH)
- Ashland Global Holdings Inc (NYSE:ASH) – Equities researchers at Truist Securiti lifted their Q4 2020 EPS estimates for shares of Ashland Global in a research note issued on Wednesday, July 29th. Truist Securiti analyst J. Sheehan now forecasts that the basic materials company will earn $0.64 per share for the quarter, up from their prior […]
- 08/04/2020
|
COVID-19 Impacts: Cosmetic Ingredients Market Will Accelerate at a CAGR of Over 7% Through 2020-2024 | Growing Demand for Natural Cosmetic Ingredients to Boost Growth | Technavio
- The Global Cosmetic Ingredients Market will grow by USD 9.16 bn during 2020-2024
- 08/04/2020
|
First Trust Advisors LP Buys 21,161 Shares of Ashland Global Holdings Inc (NYSE:ASH)
- First Trust Advisors LP grew its stake in Ashland Global Holdings Inc (NYSE:ASH) by 30.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,419 shares of the basic materials company’s stock after purchasing an additional 21,161 shares during the period. […]
- 08/03/2020
|
Ashland Global (NYSE:ASH) Price Target Raised to $90.00
- Ashland Global (NYSE:ASH) had its target price raised by research analysts at Wells Fargo & Co from $85.00 to $90.00 in a research note issued to investors on Thursday, The Fly reports. The brokerage currently has an “overweight” rating on the basic materials company’s stock. Wells Fargo & Co‘s target price suggests a potential upside […]
- 08/01/2020
|
Moving Average Crossover Alert: Ashland Global
- Ashland Global is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 07/31/2020
|
Ashland Global Holdings Inc. 2020 Q3 - Results - Earnings Call Presentation
- The following slide deck was published by Ashland Global Holdings Inc. in conjunction with their 2020 Q3 earnings call..
- 07/30/2020
|
Ashland (ASH) Earnings Miss, Sales Meet Estimates in Q3
- Ashland's (ASH) revenues decline year over year due to the effects of the prior year's business losses and unfavorable foreign currency.
- 07/30/2020
|
Ashland Global Holdings Inc. (ASH) Q3 2020 Earnings Call Transcript
- My name is Seth Mrozek, Director, Ashland Investor Relations. Joining me on the call today are Guillermo Novo, Ashland's Chairman and Chief Executive Officer; and Kevin Willis, Senior Vice President and Chief Financial Officer.
- 07/29/2020
|
Ashland Global Holdings, Inc. (ASH) CEO Guillermo Novo on Q3 2020 Results - Earnings Call Transcript
- Ashland Global Holdings, Inc. (NYSE:ASH) Q3 2020 Earnings Conference Call July 29, 2020, 09:00 AM ET Company Participants Seth Mrozek - Director, IR Guillermo Novo - Chairman and CEO John Willis - SVP and CFO Conference Call Participants John McNulty - BMO Capital Markets David Begleiter - Deutsche Bank Chris Parkinson - Credit Suisse John Roberts - UBS Mike Harrison - Seaport Global Laurence Alexander - Jefferies Jeffrey Zekauskas - JPMorgan Mike Sison - Wells Fargo Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the Ashland Global Holdings, Inc.
- 07/29/2020
|
Ashland (ASH) Q3 Earnings and Revenues Lag Estimates
- Ashland (ASH) delivered earnings and revenue surprises of -1.18% and -0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 07/28/2020
|
Ashland Global Holdings: Q3 Earnings Insights
- Shares of Ashland Global Holdings (NYSE:ASH) were flat in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were up 9.09% over the past year to $0.84, which beat the estimate of $0.68.Revenue of $574,000,000 decreased by 10.45% year over year, which beat the estimate of $561,940,000.Outlook Earnings guidance hasn't been issued by the company for now.View more earnings on ASHAshland Global Holdings hasn't issued any revenue guidance for the time being.Recent Stock Performance Company's 52-week high was at $81.82Company's 52-week low was at $38.88Price action over last quarter: Up 32.81%Company Profile Ashland Global Holdings Inc manufactures and sells a variety of specialty chemicals. The company organizes itself into three segments based on product type. The Specialty Ingredients segment, which generates the most revenue of any segment, sells cellulose ethers, vinyl pyrrolidones, and biofunctionals. Segment customers include pharmaceutical companies and manufacturers of personal care products, food and beverages, paint, coatings, and construction materials. The Valvoline segment sells automotive lubricants and chemicals and operates a chain of repair shops and quick lube oil change stores under the Valvoline brand. The Performance Materials segment sells plastic resins to automotive suppliers and electronics producers. The majority of revenue comes from North America.See more from Benzinga * Earnings Scheduled For July 28, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/28/2020
|
Ashland reports preliminary financial results for third quarter of fiscal 2020 consistent with previous update
- * Sales of $574 million, down 10% versus prior-year quarter * Net income of $37 million, or $0.61 per diluted share * Income from continuing operations of $50 million, or $0.81 per diluted share * Adjusted income from continuing operations excluding intangibles amortization expense of $68 million, or $1.12 per diluted share * Adjusted EBITDA of $143 millionWILMINGTON, Del., July 28, 2020 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced preliminary1 financial results for the third quarter of fiscal 2020 which ended June 30, 2020. The global specialty materials company serves customers in a wide range of consumer and industrial markets.As expected, the Ashland portfolio demonstrated resilience during the quarter, despite the global macroeconomic uncertainty brought on by the COVID-19 pandemic. Sales were $574 million, down 10% versus the prior-year quarter, with the previously communicated prior-year business losses representing approximately one percentage point of the decline. Unfavorable foreign currency contributed an additional one percentage point. Net income was $37 million compared to net income of $66 million in the prior-year quarter, as the prior year included earnings from the Composites and Marl businesses. Income from continuing operations was $50 million compared to income of $23 million in the prior-year quarter, or $0.81 per diluted share compared to $0.37 in the prior-year quarter. Adjusted income from continuing operations excluding intangibles amortization expense was $68 million compared to $64 million in the prior-year quarter, or $1.12 per diluted share, up from $1.04 in the prior-year quarter. Adjusted EBITDA was $143 million, up from $140 million in the prior-year quarter, as the impact of lower sales was offset by lower operating expenses and improved product mix.“Results in the third quarter were consistent with the update we issued on July 17,” said Guillermo Novo, chairman and chief executive officer, Ashland. “Our results in the quarter demonstrate the value of our leadership positions in high-quality end markets and the importance of the actions we are taking internally. Our priorities continue to be the health and safety of our employees and the continued supply of products to customers in the critical industries which we serve. Our consumer business units performed particularly well as we experienced significantly stronger demand for pharmaceutical excipients, biofunctional ingredients and additives for hand sanitizers. While our industrial businesses felt the impact of reduced global demand during April and May, the teams began to see signs of improving demand trends in June.”“Our internal actions are also driving improvements to our cost structure and profitability,” continued Novo. “The combined benefit of cost reductions, improved product mix and lower raw-material costs yielded Adjusted EBITDA growth of 2% during the quarter. Our cost-reduction plans remain on track to generate $40 million of run-rate savings by the end of the fiscal year. In addition, we plan to incur $20 million to $30 million of the previously-disclosed reduced fixed-cost absorption related to inventory-control measures during the fiscal-fourth quarter. I am confident that these continued internal actions mean we are well positioned for the upcoming fiscal year. I look forward to sharing additional thoughts on our plans and the progress we have made during the conference call with securities analysts tomorrow morning.”Reportable Segment Performance To aid in the understanding of Ashland’s ongoing business performance, the results of Ashland’s reportable segments are described below on an adjusted basis. In addition, EBITDA and adjusted EBITDA are reconciled to operating income in Table 4. Free cash flow and adjusted operating income are reconciled in Table 6 and adjusted income from continuing operations, adjusted diluted earnings per share and adjusted diluted earnings per share excluding intangible amortization expense are reconciled in Table 7 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the “Use of Non-GAAP Measures” section that further describes these adjustments below.Consumer SpecialtiesSales were $344 million, down 1% from the prior-year quarter, driven by a 3 percentage-point decline associated with previously-communicated businesses losses and a 1 percentage-point decline as a result of unfavorable foreign currency. Excluding these items, the Life Sciences and Personal Care & Household business units performed well during the quarter with particular strength demonstrated by pharmaceutical excipients, biofunctional ingredients and additives for hand sanitizers.Operating income was $56 million, compared to $49 million in the prior-year quarter. Adjusted EBITDA was $90 million, up 7% from the prior-year quarter, as lower sales volumes were more than offset by favorable price/mix and lower selling, administrative, research and development (“SARD”) costs.Industrial SpecialtiesSales were $205 million, down 23% from the prior-year quarter, due primarily to lower industrial demand across the globe reflecting the impact of the COVID-19 pandemic. Unfavorable foreign currency also reduced sales by 1%.Operating income was $28 million, compared to $35 million in the prior-year quarter. Adjusted EBITDA was $54 million, down 13% from the prior-year quarter, driven primarily by lower volume and partially offset by favorable price/mix and lower operating costs.Intermediates & SolventsSales were $37 million, down 10% from the prior-year quarter, due primarily to lower pricing on intercompany sales of butanediol and merchant-derivative sales.Operating income was $7 million, down from $8 million in the prior-year quarter. Adjusted EBITDA was $11 million, consistent with the prior-year quarter, as unfavorable price/mix was offset by favorable operating costs.Unallocated & OtherUnallocated and Other expense was $43 million, compared to $49 million in the prior-year quarter, primarily due to lower restructuring-related expenses and the elimination of stranded costs. Adjusted Unallocated and Other expense was $12 million, compared to $17 million in the prior-year quarter, primarily due to the benefits of cost reductions achieved during the previous fiscal year.OutlookChairman and CEO Guillermo Novo will provide commentary on the outlook for Ashland during the conference call with securities analysts on Wednesday, July 29, 2020.Conference Call Webcast Ashland will host a live webcast of its third-quarter conference call with securities analysts at 9:00 a.m. ET Wednesday, July 29, 2020. The webcast will be accessible through Ashland’s website at http://investor.ashland.com and will include a slide presentation. Following the live event, an archived version of the webcast and supporting materials will be available for 12 months. Use of Non-GAAP Measures Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide Ashland’s investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide disclosure on the same basis as that used by Ashland’s management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland’s historical operating performance and its business units and provide continuity to investors for comparability purposes. EBITDA margin and adjusted EBITDA margin are defined as EBITDA and adjusted EBITDA divided by sales for the corresponding period.Key items, which are set forth on Table 7 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to most accurately reflect Ashland’s underlying business performance and trends. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor’s ability to compare financial performance between reporting periods.Tax-specific key items, which are set forth on Table 7 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland’s underlying business performance and trends.The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities.
- 07/28/2020
|
Ashland's Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Ashland Global.
- 07/28/2020
|
Ashland announces definitive agreement to sell maleic anhydride business to AOC Materials, LLC for $100 million
- WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced a definitive agreement to sell the company’s maleic anhydride business and manufacturing facility in Neal, West Virginia to AOC Materials LLC, for $100 million.Maleic anhydride is manufactured industrially on a large scale for applications in coatings and polymers. The maleic anhydride business was previously excluded from the sale of Ashland’s Composites business and the butanediol (BDO) manufacturing facility in Marl, Germany, to INEOS Enterprises. The transaction with AOC is expected to close prior to the end of calendar year 2020, contingent on customary regulatory approvals and standard closing conditions.“Today’s announcement furthers Ashland’s strategic focus to streamline our portfolio and to focus on specialty ingredients and improved margins,” said Guillermo Novo, chairman and chief executive officer, Ashland. “The Maleic business and its respective employees have made important contributions to Ashland, and AOC will take a strategic view of the business to drive growth and continue their success.” “We are delighted to have this business as a part of our company and welcome the employees who have made it successful to the AOC family,” remarked Joe Salley, chief executive officer, AOC. “We are excited about the growth prospects, not only as a source for our internal consumption but also for the merchant market as well.”Citi is acting as financial advisor to Ashland, and Squire Patton Boggs LLP is acting as legal advisor.About Ashland Ashland Global Holdings Inc. (NYSE: ASH) is a premier global specialty materials company serving customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. At Ashland, we are approximately 4,600 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – who thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com to learn more. About AOC AOC is the leading global supplier of resins and specialty materials that enable customers to create robust, durable, and versatile products and components. With strong capabilities around the world in both manufacturing and science, the company works closely with customers to deliver unrivaled quality, service, and reliability for today, and create innovative solutions for tomorrow. FOR FURTHER INFORMATION:Ashland Investor Relations: Media Relations: Seth A. Mrozek Carolmarie C. Brown +1 (302) 594-5010 +1 (302) 995-3158 samrozek@ashland.com ccbrown@ashland.com AOC Media Relations: Thomas Wegman +31 38 4569565 thomas.wegman@aocresins.comAttachment * Final Ashland sells maleic anhydride business 20200726
- 07/27/2020
|
Will Ashland (ASH) Gain on Rising Earnings Estimates?
- Ashland (ASH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 07/22/2020
|
What Makes Ashland (ASH) a New Strong Buy Stock
- Ashland (ASH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 07/22/2020
|
Ashland (ASH) Expected to Beat Earnings Estimates: Should You Buy?
- Ashland (ASH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/21/2020
|
Ashland (ASH) Issues Updates for Preliminary Q3 Results
- Ashland's (ASH) financial results in the third quarter showcase the strength of its specialty materials portfolio.
- 07/21/2020
|
Ashland provides update on fiscal 2020 third-quarter earnings and sets date for fiscal 2020 third-quarter earnings release
- WILMINGTON, Del., July 17, 2020 -- Ashland Global Holdings Inc. (NYSE: ASH) today provided an update for preliminary fiscal 2020 third-quarter financial results. Additional.
- 07/17/2020
|
Ashland Global Holdings Inc (NYSE:ASH) Shares Purchased by Louisiana State Employees Retirement System
- Louisiana State Employees Retirement System grew its stake in shares of Ashland Global Holdings Inc (NYSE:ASH) by 3.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,100 shares of the basic materials company’s stock after acquiring an additional 500 shares […]
- 07/16/2020
|
COVID-19 Impact & Recovery Analysis - Fracking Fluid Market (2020-2024) | Increasing Demand for Oil and Gas to Boost Growth | Technavio
- The GLOBAL FRACKING FLUID MARKET will grow by USD 14.72 bn during 2020-2024
- 07/16/2020
|
Global Acrylamide Market to 2027 - The US Accounts for Over 27% of the Market in 2020 - ResearchAndMarkets.com
|
ASH or LTHM: Which Is the Better Value Stock Right Now?
- ASH vs. LTHM: Which Stock Is the Better Value Option?
- 07/14/2020
|
Did Hedge Funds Make The Right Call On Ashland Global Holdings Inc.. (ASH) ?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 07/11/2020
|
Aviator appoints new GM - Hospitality & Catering News
- Aviator appoints new GM: Adam Skrzypczak is the new Aviator General Manager, bringing with him four and a half invaluable years’ contribution as Director...
- 06/26/2020
|
Insights & Forecast with Potential Impact of COVID-19 - Corrosion and Scale Inhibitors Market 2020-2024 | Increased Demand for Corrosion and Scale Inhibitors to Boost Growth | Technavio
- The Global Corrosion and Scale Inhibitors Market will grow by USD 2.59 bn during 2020-2024
- 06/24/2020
|
Global Polymer Based Solubility Enhancement Excipients Market for OSDF 2020-2024 | Increasing Global Geriatric Population to Boost Growth | Technavio
- The Global Polymer Based Solubility Enhancement Excipients Market for OSDF will grow by USD 1.83 bn during 2020-2024
- 06/23/2020
|
Asset Management One Co. Ltd. Sells 998 Shares of Ashland Global Holdings Inc (NYSE:ASH)
- Asset Management One Co. Ltd. cut its holdings in shares of Ashland Global Holdings Inc (NYSE:ASH) by 8.6% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,544 shares of the basic materials company’s stock after selling 998 shares during the period. Asset Management […]
- 06/17/2020
|
Ashland Global Holdings Inc (NYSE:ASH) Shares Sold by Parametric Portfolio Associates LLC
- Parametric Portfolio Associates LLC reduced its stake in shares of Ashland Global Holdings Inc (NYSE:ASH) by 18.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 196,073 shares of the basic materials company’s stock after selling 44,054 shares during […]
- 06/16/2020
|
Treasurer of the State of North Carolina Acquires 8,340 Shares of Ashland Global Holdings Inc (NYSE:ASH)
- Treasurer of the State of North Carolina lifted its holdings in shares of Ashland Global Holdings Inc (NYSE:ASH) by 57.5% in the first quarter, according to its most recent filing with the SEC. The firm owned 22,856 shares of the basic materials company’s stock after acquiring an additional 8,340 shares during the period. Treasurer of […]
- 06/14/2020
|
The Top Stocks To Buy On A Crash
- Growing volatility creates opportunities in the best stocks and sectors. Healthcare and technology remain top sectors to buy. Here are the best stocks to buy in
- 06/12/2020
|
Burden of COVID-19 on the Market & Rehabilitation Plan | Cosmetic Ingredients Market 2020-2024 | The Growing Demand For Natural And Organic Cosmetic Ingredients to Boost Growth | Technavio
- The Global Cosmetic Ingredients Market will grow by $ 9.16 bn during 2020-2024
- 06/12/2020
|
Ashland Recognized for Sustainability Leadership by ACC | WholeFoods Magazine
- Wilmington, DE—The American Chemistry Council (ACC) has recognized Ashland Global Holdings Inc. with a sustainability leadership award for environmental protection and circularity, according to a press release. The award was presented during the ACC Annual Meeting, which was held virtually due to COVID-19. The ACC judging panel was comprised of external sustainability leaders from consumer […]
- 06/09/2020
|
Dividend Champion And Contender Highlights: Week Of June 7
- A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
- 06/06/2020
|
Hedge Funds Buying Ashland Global Holdings Inc. (ASH)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/05/2020
|
American Chemistry Council recognizes Ashland with a 2020 sustainability leadership award for environmental protection and circularity
- WILMINGTON, Del., June 03, 2020 -- The American Chemistry Council (ACC) has recognized Ashland Global Holdings Inc. (NYSE: ASH) with a sustainability leadership award for.
- 06/03/2020
|
American Chemistry Council recognizes Ashland with a —…—… sustainability leadership ...
|
More Companies Skip Dividend Increases In Second Half Of May As Uncertainties Continue
- More companies continue to risk falling off the list of dividend growth stocks as they hold payouts steady. While 5 of 8 expected increases in late May failed t
- 06/02/2020
|
Global Concrete Admixtures Market 2020-2024 | Increasing Demand for Plasticizers to Boost Growth | Technavio
- The Global Concrete Admixtures Market will grow by $ 3.54 bn during 2020-2024
- 06/02/2020
|
Dividend Champion And Contender Highlights: Week Of May 24
- A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
- 05/23/2020
|
Ashland announces general counsel transition
- Ashland Global Holdings Inc. (ASH) today announced that the board of directors has approved the appointment of Yvonne Winkler von Mohrenfels as general counsel and secretary effective Jan. 1, 2021. As part of the company’s ongoing transformation, Peter J. Ganz, senior vice president, general counsel and secretary, and chief legal and compliance officer has elected to retire from Ashland at the end of the calendar year.
- 05/22/2020
|
Ashland announces general counsel transition
|
Ashland board declares quarterly dividend
- WILMINGTON, Del., May 20, 2020 -- The board of directors of Ashland Global Holdings Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.275 per share on the company's.
- 05/20/2020
|
Ashland board declares quarterly dividend
|
Should You Take Comfort From Insider Transactions At Ashland Global Holdings Inc. (NYSE:ASH)?
- It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- 05/18/2020
|
Causeway Capital Management Llc Buys Coca-Cola European Partners PLC, Broadcom Inc, Ryanair ...
|
Ashland's (ASH) Q2 Earnings In Line, Revenues Beat Estimates
- Ashland's (ASH) Q2 revenues were hurt by business losses in oral care and the legacy Pharmachem business.
- 05/12/2020
|
SunTrust Robinson Humphrey Maintains Buy on Ashland Global Holdings, Lowers Price Target to $75
|
U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies
- Wall Street securities analysts on Thursday revised their ratings and
price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and
Solaredge Technologies.
HIGHLIGHTS
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Lyft Inc : Piper Sandler cuts to neutral from overweight
* Natera Inc : JP Morgan raises to overweight from neutral
* Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell
* Solaredge Technologies : Canaccord Genuity cuts to hold from buy
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday.
Stock entries are in alphabetical order.
* A. O. Smith Corp : Stephens raises target price to $40 from $37
* Acadia Healthcare Company Inc : Citigroup cuts price target to $34 from $37
* Acadia Healthcare Company Inc : Deutsche Bank cuts target price to $28 from $32
* Activision Blizzard Inc : Keybanc raises target price to $80 from $68
* Adient Plc : Deutsche Bank raises target price to $20 from $15
* ADMA Biologics Inc : Oppenheimer cuts target price to $7 from $14
* Advanced Energy Industries Inc : Citigroup raises price target to $63 from $40
* Advanced Energy Industries Inc : Cowen and Company raises PT to $58 from $51
* Advanced Energy Industries Inc : D.A. Davidson raises target to $60 from $50
* Advanced Energy Industries Inc : Susquehanna cuts target price to $85 from $90
* Aerie Pharmaceuticals Inc : H.C. Wainwright cuts target price to $31 from $37
* Aerie Pharmaceuticals Inc : Mizuho cuts target price to $29 from $34
* Aerie Pharmaceuticals Inc : Piper Sandler cuts target price to $35 from $45
* Aerie Pharmaceuticals Inc : SunTrust Robinson cuts price target to $22 from $26
* Agco Corp : Stephens raises target price to $65 from $60
* Air Transport Services Group Inc : Cowen and Company raises PT to $26 from $25
* Albemarle Corp : UBS cuts target price to $90 from $98
* Alexion Pharmaceuticals Inc : BMO cuts target price to $142 from $147
* Alexion Pharmaceuticals Inc : Credit Suisse cuts target price to $142 from $147
* Alexion Pharmaceuticals Inc : Jefferies cuts price target to $111 from $112
* Alexion Pharmaceuticals Inc : Raymond James cuts target price to $156 from $159
* Alexion Pharmaceuticals Inc : SunTrust Robinson cuts target to $135 from $141
* Alexion Pharmaceuticals Inc : SVB Leerink cuts target price to $150 from $156
* Allegiant Travel Co : Cowen and Company cuts price target to $74 from $100
* Allete Inc : Guggenheim cuts price target to $65 from $70
* Allogene Therapeutics Inc : Jefferies raises target price to $37 from $36
* Allstate Corp : Piper Sandler raises target price to $112 from $108
* Alnylam Pharmaceuticals Inc : Guggenheim raises price target to $166 from $155
* Alnylam Pharmaceuticals Inc : BMO raises target price to $171 from $145
* Alnylam Pharmaceuticals Inc : Jefferies raises price target to $165 from $142
* Alnylam Pharmaceuticals Inc : JP Morgan cuts to neutral from overweight
* Alnylam Pharmaceuticals Inc : JP Morgan raises target price to $137 from $133
* Alnylam Pharmaceuticals Inc : Needham raises target price to $160 from $135
* Alnylam Pharmaceuticals Inc : Oppenheimer raises target price to $162 from $140
* Alnylam Pharmaceuticals Inc : Piper Sandler raises target to $169 from $142
* Alteryx Inc : Citigroup cuts price target to $147 from $160
* Alteryx Inc : Cowen and Company cuts target price to $135 from $145
* Alteryx Inc : Needham cuts target price to $140 from $152
* Alteryx Inc : Wedbush cuts price target to $138 from $146
* Amedisys Inc : Benchmark cuts to hold rating
* Ameriprise Financial Inc : Evercore ISI raises target price to $139 from $136
* Ametek Inc : Berenberg raises target price to $93 from $86
* Ametek Inc : Stephens cuts target price to $92 from $94
* Anaptysbio Inc : Credit Suisse raises target price to $16 from $14
* Apache Corp : Credit Suisse raises target price to $10 from $4
* Aptiv Plc : Deutsche Bank raises target price to $75 from $59
* Arcus Biosciences Inc : Wedbush raises target price to $40 from $26
* Ares Capital Corp : BMO cuts target price by $5 to $16
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Ares Management Corp : BMO raises target price to $40 from $30
* Ares Management Corp : Credit Suisse raises target price to $40 from $38
* Ares Management Corp : Jefferies raises target price to $42 from $39
* Ares Management Corp : KBW raises target price to $45 from $44
* ASGN Inc : Jefferies raises target price to $54 from $31
* Ashland Global Holdings Inc : Deutsche Bank raises target price to $70 from $65
* Ashland Global Holdings Inc. : JP Morgan cuts target price to $62 from $68
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Ashland Global Holdings Inc. : SunTrust Robinson cuts price target to $75 from $87
* Aspen Technology Inc : Benchmark cuts target price to $130
* Aspen Technology Inc : Keybanc raises target price to $120 from $110
* Assetmark Financial Holdings Inc : BMO cuts target price to $23 from $26
* Assurant Inc : SunTrust Robinson cuts price target to $145 from $155
* Astronics Corp : Canaccord Genuity cuts target price to $10 from $14
* Astronics Corp : SunTrust Robinson cuts price target to $6 from $7
* Atkore International Group Inc : Citigroup raises price target to $26 from $24
* Atlas Corp (British Columbia) : Citigroup cuts price target to $7 from $12
* Avanos Medical Inc : Berenberg raises target price to $33 from $30
* Avanos Medical Inc : Stephens raises target price to $38 from $30
* Axalta Coating Systems Ltd : Citigroup raises price target to $21 from $18
* Axalta Coating Systems Ltd : Credit Suisse cuts target price to $27 from $29
* Axalta Coating Systems Ltd : Jefferies raises target price to $18 from $15
* Axalta Coating Systems Ltd : Keybanc raises target price to $24 from $23
* Axcelis Technologies Inc : D.A. Davidson raises price target to $25 from $20
* Axcella Health Inc : BTIG raises target price to $12 from $10
* Axogen Inc : Canaccord Genuity cuts target price to $12 from $22
* Axogen Inc : Jefferies cuts target price to $21 from $30
* Bank of N.T. Butterfield & Son Ltd : Citigroup raises target to $21 from $15
* Barrett Business Services Inc : Barrington Research raises PT to $52 from $48
* Barrick Gold Corp : Deutsche Bank raises target price to $34 from $25
* Benefitfocus Inc : Piper Sandler cuts target price to $26 from $35
* Bio Rad Laboratories Inc : Citigroup raises price target to $525 from $480
* Bio Rad Laboratories Inc : Jefferies raises target price to $525 from $500
* Biocryst Pharmaceuticals Inc : Jefferies raises price target to $9 from $8
* Biocryst Pharmaceuticals Inc : Piper Sandler raises target price to $10 from $8
* Biotelemetry Inc : Benchmark cuts target price to $52 from $55
* Black Knight Inc : KBW raises target price to $70 from $68
* Black Knight Inc : Stephens raises target price to $88 from $84
* Black Knight Inc : Wedbush raises target price to $70 from $66
* Black Stone Minerals LP : Simmons Energy raises target price to $8 from $5
* Blackbaud Inc : Evercore ISI cuts target price to $48 from $55
* Blucora Inc : Benchmark cuts price target to $25 from $37
* BMC stock Holdings Inc : Stephens raises target price to $25 from $22
* BMC stock Holdings Inc : SunTrust Robinson raises price target to $26 from $22
* BorgWarner Inc : Jefferies raises target price to $33 from $30
* BorgWarner Inc : JP Morgan raises price target to $35 from $32
* BorgWarner Inc : Oppenheimer cuts target price to $44 from $45
* BorgWarner Inc : RBC raises target price to $31 from $29
* Boston Private Financial Holdings Inc : Piper Sandler raises PT to $7 from $6.
- 05/07/2020
|
Benzinga's Top Upgrades, Downgrades For May 7, 2020
|
Deutsche Bank Maintains Buy on Ashland Global Holdings, Raises Price Target to $70
|
JP Morgan Upgrades Ashland Global Holdings to Neutral, Lowers Price Target of $62
|
Ashland Inc (ASH) Q2 2020 Earnings Call Transcript
- ASH earnings call for the period ending March 31, 2020.
- 05/07/2020
|
U.S. RESEARCH ROUNDUP-Ashland Global Holdings, Lyft, Solaredge Technologies
- Wall Street securities analysts revised their ratings and price targets on
several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge
Technologies, on Thursday.
HIGHLIGHTS
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Lyft Inc : Piper Sandler cuts to neutral from overweight
* Natera Inc : JP Morgan raises to overweight from neutral
* Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell
* Solaredge Technologies : Canaccord Genuity cuts to hold from buy
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday.
Stock entries are in alphabetical order.
* Acadia Healthcare Company Inc : Citigroup cuts price target to $34 from $37
* Activision Blizzard Inc : Keybanc raises target price to $80 from $68
* Advanced Energy Industries Inc : Susquehanna cuts target price to $85 from $90
* Agco Corp : Stephens raises target price to $65 from $60
* Alexion Pharmaceuticals Inc : Credit Suisse cuts target price to $142 from $147
* Allegiant Travel Co : Cowen and Company cuts price target to $74 from $100
* Allstate Corp : Piper Sandler raises target price to $112 from $108
* Alnylam Pharmaceuticals Inc : JP Morgan cuts to neutral from overweight
* Alnylam Pharmaceuticals Inc : JP Morgan raises target price to $137 from $133
* Alnylam Pharmaceuticals Inc : Needham raises target price to $160 from $135
* Alnylam Pharmaceuticals Inc : Piper Sandler raises target price to $169 from $142
* Anaptysbio Inc : Credit Suisse raises target price to $16 from $14
* Arcus Biosciences Inc : Wedbush raises target price to $40 from $26
* Ares Management Corp : Credit Suisse raises target price to $40 from $38
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Ashland Global Holdings Inc. : JP Morgan cuts target price to $62 from $68
* Aspen Technology Inc : Keybanc raises target price to $120 from $110
* Astronics Corp : Canaccord Genuity cuts target price to $10 from $14
* Atkore International Group Inc : Citigroup raises price target to $26 from $24
* Atlas Corp (British Columbia) : Citigroup cuts price target to $7 from $12
* Axalta Coating Systems Ltd : Credit Suisse cuts target price to $27 from $29
* Axalta Coating Systems Ltd : Keybanc raises target price to $24 from $23
* Axogen Inc : Canaccord Genuity cuts target price to $12 from $22
* Bank of N.T. Butterfield & Son Ltd : Citigroup raises price target to $21 from $15
* Benefitfocus Inc : Piper Sandler cuts target price to $26 from $35
* Biocryst Pharmaceuticals Inc : Piper Sandler raises target price to $10 from $8
* Black Knight Inc : Stephens raises target price to $88 from $84
* Black Stone Minerals LP : Simmons Energy raises target price to $8 from $5
* Boston Private Financial Holdings Inc : Piper Sandler raises PT to $7 from $6.50
* Brookfield Business Partners LP : National Bank of Canada cuts PT to $38 from $42
* Brookfield Renewable Partners LP : CIBC raises target price to $49 from $48
* Catalent Inc : Stephens raises target price to $82 from $75
* Central Garden & Pet Co : Keybanc raises target price to $38 from $35
* Ceridian Hcm Holding Inc : Credit Suisse raises target price to $49 from $47
* Chefs' Warehouse Inc : Jefferies raises target price to $13 from $12
* Chemours Co : Jefferies raises target price to $13 from $11
* CNH Industrial : JP Morgan cuts target price to $6.50 from $8
* Consolidated Edison Inc : Credit Suisse cuts target price to $78 from $92
* Constellation Pharmaceuticals Inc : Jefferies raises target price to $63 from $53
* Lendingclub Corp : BTIG cuts target price to $11 from $23
* Cubic Corp : Canaccord Genuity cuts target price to $48 from $55
* Cytosorbents Corp : MKM Partners raises target price to $14 from $8
* Devon Energy Corp : Simmons Energy raises target price to $10 from $6
* Discovery Inc : MKM Partners cuts target price to $26 from $30
* Dupont : Citigroup raises price target to $52 from $47
* Dupont : Jefferies raises target price to $53 from $49
* Elevate Credit Inc : Credit Suisse cuts target price to $4 from $4.75
* Etsy Inc : Canaccord Genuity raises target price to $85 from $70
* Etsy Inc : Jefferies raises target price to $71 from $66
* Everbridge Inc : Stephens raises target price to $125 from $120
* Eversource Energy : Credit Suisse cuts target price to $81 from $92
* Evoqua Water Technologies Corp : Stifel raises target price to $22 from $21
* Exact Sciences Corp : Cowen and Company raises target price to $95 from $90
* Fastly Inc : Piper Sandler raises target price to $31 from $27
* First Western Financial Inc : Stephens cuts target price to $15 from $17
* Flir Systems Inc : Needham raises target price to $52 from $48
* FMC Corp : Citigroup raises price target to $114 from $107
* FMC Corp : Keybanc raises target price to $108 from $93
* Formfactor Inc : Cowen and Company raises target price to $24 from $22
* Formfactor Inc : D.A. Davidson raises target price to $25 from $20
* Fortinet Inc : Credit Suisse raises target price to $110 from $100
* Fortinet Inc : Piper Sandler raises target price to $125 from $110
* Fox Factory Holding Corp : Jefferies raises target price to $65 from $60
* Frontdoor Inc : Credit Suisse cuts target price to $44 from $50
* Gibraltar Industries Inc : Keybanc cuts target price to $55 from $60
* Global Payments Inc : Credit Suisse raises target price to $200 from $190
* Global Payments Inc : Jefferies raises target price to $195 from $175
* Global Payments Inc : Susquehanna raises target price to $205 from $200
* Graftech International Ltd : Credit Suisse cuts target price to $13 from $17
* Grubhub Inc : Jefferies raises target price to $50 from $48
* Heron Therapeutics Inc : Jefferies cuts target price to $31 from $33
* Hubspot Inc : Jefferies raises target price to $202 from $150
* Immunomedics Inc : Jefferies raises target price to $41 from $25
* Inmode Ltd : Canaccord Genuity cuts target price to $40 from $50
* Kennametal Inc : CFRA cuts target price to $25 from $32
* Kennametal Inc : JP Morgan cuts target price to $27 from $31
* Kforce Inc : Credit Suisse raises target price to $32 from $26
* KKR & Co Inc : Credit Suisse raises target price to $29 from $27
* Livongo Health Inc : Canaccord Genuity raises target price to $65 from $46
* Livongo Health Inc : Keybanc raises target price to $52 from $46
* Lyft Inc : D.A. Davidson raises target price to $35 from $27
* Lyft Inc : Jefferies cuts target price to $50 from $60
* Lyft Inc : Piper Sandler cuts price target to $31 from $63
* Lyft Inc : Piper Sandler cuts to neutral from overweight
* Magellan Midstream Partners LP : Credit Suisse raises target price to $48 from $42
* Martin Marietta Materials Inc : Citigroup raises price target to $230 from $228
* Natera Inc : Canaccord Genuity raises target price to $48 from $46
* Natera Inc : JP Morgan raises to overweight from neutral
* Natera Inc : JP Morgan raises target price to $45 from $32
* National Energy Services Reunited : National Bank of Canada cuts PT to $12 from
$13
* Neurocrine Biosciences Inc : Canaccord Genuity raises target to $123 from $122
* Neurocrine Biosciences Inc : Jefferies raises target price to $119 from $115
* Neurocrine Biosciences Inc : Mizuho raises target price to $105 from $103
* Neurocrine Biosciences Inc : Piper Sandler raises target price to $126 from $125
* Nlight Inc : Canaccord Genuity cuts target price to $22 from $25
* Now Inc : Stifel cuts target price to $6 from $7
* Nuvasive Inc : Canaccord Genuity cuts target price to $64 from $68
* Nuvasive Inc : Piper Sandler cuts target price to $75 from $90
* Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell
* Occidental Petroleum Corp : SunTrust Robinson raises price target to $13 from $10
* Occidental Petroleum Corp : Susquehanna cuts target price to $12 from $13
* Palomar Holdings Inc : Piper Sandler raises target price to $64 from $54
* Papa John's International Inc : Credit Suisse raises target price to $84 from $71
* Papa John's International Inc : MKM Partners raises target price to $72 from $70
* Papa John's International Inc : Stifel raises target price to $95 from $80
* Parsley Energy Inc : Simmons Energy raises target price to $8 from $7.
- 05/07/2020
|
UBS Maintains Buy on Ashland Global Holdings, Raises Price Target to $71
|
Ashland Sees Prelim. Q2 Adj. EPS $0.84 vs $0.81 Est., Sales $610M vs $618.76M Est.
|
Ashland reports preliminary financial results for second quarter of fiscal 2020 consistent with previous update
- Ashland Global Holdings Inc. (ASH) today announced preliminary1 financial results for the second quarter of fiscal 2020 ended March 31, 2020. As expected, the Ashland portfolio performed well during the quarter, despite the global macroeconomic uncertainty brought on by the COVID-19 pandemic.
- 05/05/2020
|
Earnings Scheduled For May 5, 2020
|
Ashland reports preliminary financial results for second quarter of fiscal —…—… ...
|
How this Week’s Premium Top 10 Performed, May 1, 2020
- How this Week’s Premium Top 10 Performed, May 1, 2020
Posted by
Greg Harmon
on May 1st, 2020
Each week I post the performance of the stocks that were given to subscribers the previous Sunday. All performance is measured against the plan given to subs
- 05/01/2020
|
Mapping Ohio’s 18,743 coronavirus cases, updates and trends
- Ohio’s 1,002 known coronavirus-related deaths are spread across 60 counties, with cases in all 88 counties.
- 05/01/2020
|
Why We’re Not Impressed By Ashland Global Holdings Inc.’s (NYSE:ASH) 3.4% ROCE
- Today we are going to look at Ashland Global Holdings Inc. (NYSE:ASH) to see whether it might be an attractive...
- 05/01/2020
|
Urban/rural: Known coronavirus cases 3 times more likely per capita in Ohio’s biggest counties than the smallest
- Ohio's urban/rural trend follows what has occurred in places like New York City and the Detroit metro area.
- 05/01/2020
|
2020 Food Texture Materials Industry Report - Growing Consumer Preference for Convenience and Packaged Food Products - ResearchAndMarkets.com
- The "Food Texture Materials Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
- 05/01/2020
|
Mapping Ohio’s 18,027 coronavirus cases, updates and trends
- Ohio’s 975 known coronavirus-related deaths are spread across 59 of the state’s 88 counties, with total cases now reaching 18,027.
- 04/30/2020
|
The Global Specialty Chemical Market is expected to grow from USD 201,847.32 Million in 2018 to USD 284,313.32 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.01%
- The Global Specialty Chemical Market is expected to grow from USD 201,847.32 Million in 2018 to USD 284,313.32 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.01%. Read the full report: https://www.reportlinker.com/p05871478/?utm_source=PRN The positioning of the Global Specialty
- 04/29/2020
|
The 30 Best Wallets for Men
- Wallets come in all shapes and sizes but one thing is certain: they're an essential part of every guy's EDC. This guide covers the best wallets in a variety of styles, including slim and minimalist designs.
- 04/29/2020
|
Mapping Ohio’s 16,769 coronavirus cases, updates, trends
- Coronavirus cases reported in every Ohio county, deaths if 59 of 88 counties
- 04/28/2020
|
Ashland (ASH) Earnings Expected to Grow: Should You Buy?
- Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Ashland (ASH) Earnings Expected to Grow: Should You Buy?
- Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Man fatally shot by police outside hospital is identified
- WAUKESHA, Wis. (AP) — Police have identified the man who was fatally shot by police outside a Waukesha hospital. Randy Ashland, 58, was shot April 15 outside Waukesha Memorial Hospital. Police responded to a report of a man with a gun in the parking lot of the hospital and found Ashland armed with a handgun near the entrance to the emergency department. The hospital was locked down as officers talked with Ashland, repeatedly asking him to drop the gun. Police said he aimed the weapon at officers, who opened fire. An autopsy confirmed Ashland died from the gunfire.
- 04/28/2020
|
Ashland Global (ASH) Scheduled to Post Quarterly Earnings on Tuesday
- Ashland Global (NYSE:ASH) is scheduled to release its earnings data after the market closes on Tuesday, May 5th. Analysts expect Ashland Global to post earnings of $0.74 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link. Ashland Global (NYSE:ASH) last announced its quarterly […]
- 04/28/2020
|
Ohio’s reopening plan begins with hospitals, construction, manufacturing: The Wake Up for Tuesday, April 28, 2020
- Starting May 1, Gov. Mike DeWine will allow all hospital procedures that do not require an overnight stay to resume. On May 4, construction and manufacturing will resume with social distancing, hygiene, cleaning and other measures to protect workers and customers and their families. Read about this and more in cleveland.com's newsletter The Wake Up.
- 04/28/2020
|
Ashland (ASH) Earnings Expected to Grow: Should You Buy?
|
Ashland announces time change for its second-quarter fiscal 2020 earnings conference call and webcast
- WILMINGTON, DELAWARE, April 27, 2020 -- Ashland Global Holdings Inc. (NYSE: ASH) today announced that its second-quarter earnings conference call and webcast will now take.
- 04/27/2020
|
Ashland announces time change for its second-quarter fiscal 2020 earnings conference call and webcast
- WILMINGTON, DELAWARE, April 27, 2020 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE: ASH) today announced that its second-quarter earnings...
- 04/27/2020
|
Mapping Ohio’s 16,325 coronavirus cases, Monday’s update, trends
- Coronavirus cases in 87 of 88 cases, with deaths in 59 counties.
- 04/27/2020
|
Report: Former aluminum mill CEO misled investors, board
- ASHLAND, Ky. (AP) — The former CEO of a Kentucky aluminum company planning to build a plant in Appalachia misled potential investors and the company’s board and even tried to fool journalists visiting the construction site, according to a report. The report, written by a law firm as a part of a legal fight between the company and former Braidy Industries CEO Craig Bouchard, said Braidy only had $11 million cash on hand in January and would run out of money by midyear. Bouchard also told investors the proposed mill in Ashland could be moved to Mexico, the report said. A copy of the 49-page report was obtained by The Daily Independent in Ashland. It paints an unflattering picture of the business practices of Bouchard, who was ousted by Braidy’s board of directors on Jan. 28. Bouchard alleged in a lawsuit filed in February in Delaware that several defendants breached their obligations under a company voting agreement after refusing his efforts to remove four executives from Braidy’s board. The report the newspaper obtained was part of the filings in that lawsuit. The law firm Frost Brown Todd interviewed former employees, the board and reviewed 17,000 documents to complete the report. “Each board member interviewed described the same pattern of conduct: Mr. Bouchard would provide an impressive list of purported interested investors. He would report that at least one of the investors would invest in Braidy imminently. That investment did not occur,” the report said. Investors from Japan, Abu Dhabi, Saudi Arabia, Oman, South Korea and India were all mentioned as potential deals, but none materialized, the report said. Kentucky taxpayers have a direct stake in Braidy’s plans to build the aluminum rolling mill near Ashland, Kentucky. During his term as governor, Republican Matt Bevin persuaded Kentucky...
- 04/27/2020
|
Ohio Supreme Court rules courtroom trial can go forward despite coronavirus concerns
- The Ohio Supreme Court on Monday ruled that an Ashland County courtroom trial can go forward this week so long as social-distancing precautions are taken.
- 04/27/2020
|
Wayne Savings Bancshares, Inc. Announces Earnings for the first quarter 2020
- WOOSTER, Ohio, April 27, 2020 -- Wayne Savings Bancshares, Inc. (OTCQX: WAYN), (the “Company”), the holding company parent of Wayne Savings Community Bank, reported net income.
- 04/27/2020
|
Insights on the US Construction Chemicals Industry to 2025 - Featuring 3M, ADCO, Arkema Group & Ashland Among Others
- Dublin, April 27, 2020 -- The "United States Construction Chemicals Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to.
- 04/27/2020
|
- MASKS are here to stay – How coronavirus spread in CHELSEA – MORSE calls for state TAKEOVER of nursing homes
GOOD MORNING, MASSACHUSETTS
. Happy Monday!
BAKER: MASKS KEY WHEN MASS. REOPENS —
We’re a week away from when the Massachusetts stay-at-home
- 04/27/2020
|
Ashland announces time change for its second-quarter fiscal —…—… earnings conference ...
|
Mapping Ohio’s 15,963 coronavirus cases, Sunday’s update, trends
- Ohio's coronavirus cases are spread across 87 of 88 counties, with deaths in 58 counties.
- 04/26/2020
|
5 Trade Ideas for Monday: Alexion Pharmaceuticals, Ashland, Lowe’s, Marathon Oil and Uber
- 5 Trade Ideas for Monday:
Alexion Pharmaceuticals, Ashland, Lowe’s, Marathon Oil and Uber
Posted by
Greg Harmon
on April 26th, 2020
5 Trade ideas excerpted
from the detailed analysis and plan for premium subscribers:
Alexion Pharmaceuticals, Ticker:
- 04/26/2020
|
Top Trade Ideas for the Week of April 27, 2020: The Rest Premium
|
Mapping Ohio’s 15,587 coronavirus cases, Saturday’s update, trends
- Ohio's coronavirus cases are in 87 of 88 counties, with deaths in 57 counties.
- 04/25/2020
|
Small earthquake strikes southern Oregon, no damage reported
- ASHLAND, Ore. (AP) — A magnitude-3.1 earthquake struck in southern Oregon near Ashland, officials said. Just before 10 a.m. Friday, the quake rumbled about 10 miles (16 kilometers) southwest of Ashland at a depth of 1.6 miles, according to the...
- 04/24/2020
|
Mapping Ohio’s 15,169 coronavirus cases, Friday’s update, trends
- Death, hospitalization and other trends for COVID-19 in Ohio.
- 04/24/2020
|
The Global Unsaturated Polyester Resins Market is expected to grow from USD 9,194.40 Million in 2018 to USD 13,849.36 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.02%
- The Global Unsaturated Polyester Resins Market is expected to grow from USD 9,194.40 Million in 2018 to USD 13,849.36 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.02%. Read the full report: https://www.reportlinker.com/p05871586/?utm_source=PRN The positioning of the Global
- 04/24/2020
|
The Global Underwater Concrete Market is expected to grow from USD 125,938.58 Million in 2018 to USD 201,849.06 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.97%
- New York, April 24, 2020 -- Reportlinker.com announces the release of the report "Global Underwater Concrete Market - Premium Insight, Competitive News Feed Analysis, Company.
- 04/24/2020
|
CD One Price Cleaners Cleans 25,000 Pounds of Laundry for Free for 1,000 Healthcare Workers and First Responders
- CD One Price Cleaners has extended its offer of free laundry to healthcare workers, police, firefighters, and EMTs so that they can rest, refresh, and remain focused on serving the community, until the end of May.
- 04/24/2020
|
Mapping Ohio’s 14,694 coronavirus cases, updates and trends
- COVID-19 cases are in 87 of 88 Ohio counties, with deaths 56 counties.
- 04/23/2020
|
Valvoline Announces Timing of Second-Quarter Financial Results and Provides COVID-19 Business Update
- Valvoline Inc. (NYSE: VVV), a leading worldwide supplier of premium branded lubricants and automotive services, today announced the date and time of its fiscal second-quarter 2020 earnings release and provided an update on the impacts of the novel coronavirus (COVID-19) pandemic.
- 04/23/2020
|
Ashland Global Holdings Inc (NYSE:ASH) Expected to Post Quarterly Sales of $609.36 Million
- Wall Street brokerages expect Ashland Global Holdings Inc (NYSE:ASH) to post $609.36 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Ashland Global’s earnings, with the lowest sales estimate coming in at $607.87 million and the highest estimate coming in at $610.20 million. Ashland Global reported sales of […]
- 04/23/2020
|
Mapping Ohio’s 14,117 coronavirus cases, updates and trends
- COVID-19 cases are spread across 87 of 88 counties, with deaths in more than half.
- 04/22/2020
|
Mapping 13,725 Ohio’s coronavirus cases, updates and trends
- COVID-19 cases identified in 87 of Ohio's 88 counties; deaths 50 counties.
- 04/21/2020
|
Restitution returned to doctor after conviction overturned
- ASHLAND, Ky. (AP) — The federal government has agreed to return $1.1 million a doctor paid in restitution money after an appeals court overturned his conviction on health care fraud charges, according to court documents. U.S. District Judge David L. Bunning signed the order last week to return the money to former Ashland cardiologist Richard Paulus, The Daily Independent reported. The Sixth Circuit Court of Appeals overturned his conviction March 5 and Paulus was released from a federal penitentiary. Federal prosecutors charged Paulus with performing unnecessary heart procedures as part of a healthcare fraud scheme in Eastern Kentucky. He was a cardiologist at King’s Daughters Medical Center in Ashland when authorities received an anonymous complaint about the procedures. A jury convicted him in 2016, but a series of legal wranglings followed that saw the conviction reversed, reinstated and overturned. According to the latest appeals court ruling, federal prosecutors withheld a letter from Paulus that showed about 75 out of 1,049 stent procedures were flagged as unnecessary, which is lower than what government witnesses had said at trial. A hearing has not been scheduled in the case due to court restrictions implemented because of the coronavirus pandemic, but deadlines have been set for written motions, including a motion to dismiss by attorneys representing Paulus.
- 04/21/2020
|
Jaguars history: Minshew may be team’s top late-round pick
- JACKSONVILLE, Fla. (AP) — BEST FIRST-ROUND DRAFT PICK: RB Fred Taylor. A rare combination of size, speed and elusiveness had Taylor routinely mentioned among the best backs of his era. The former Florida standout was the ninth pick in 1998...
- 04/21/2020
|
Seaport Global Securities Equities Analysts Reduce Earnings Estimates for Ashland Global Holdings Inc (NYSE:ASH)
- Ashland Global Holdings Inc (NYSE:ASH) – Equities researchers at Seaport Global Securities cut their Q2 2021 earnings per share (EPS) estimates for Ashland Global in a report issued on Friday, April 17th. Seaport Global Securities analyst M. Harrison now forecasts that the basic materials company will post earnings of $1.04 per share for the quarter, […]
- 04/21/2020
|
Albemarle Announces J. Kent Masters Elected Chairman, President and Chief Executive Officer
- Albemarle Corporation (NYSE: ALB), a leader in the global specialty chemicals industry, announced today that J. Kent Masters has been elected Chairman, President and Chief Executive Officer (CEO), effective immediately.
- 04/20/2020
|
Mapping Ohio’s 12,919 coronavirus cases, updates and trends
- 509 die of COVID-19 across 50 Ohio counties.
- 04/20/2020
|
Q2 2020 Earnings Estimate for Ashland Global Holdings Inc (NYSE:ASH) Issued By Jefferies Financial Group
- Ashland Global Holdings Inc (NYSE:ASH) – Analysts at Jefferies Financial Group raised their Q2 2020 earnings per share (EPS) estimates for shares of Ashland Global in a research note issued on Thursday, April 16th. Jefferies Financial Group analyst L. Alexander now expects that the basic materials company will post earnings per share of $0.84 for […]
- 04/20/2020
|
Mapping Ohio’s 11,602 coronavirus cases, Sunday’s updates and trends
- Coronavirus has killed people in more than half of Ohio's counties.
- 04/19/2020
|
Mapping Ohio’s 10,222 coronavirus cases, Saturday’s updates and trends
- COVID-19 has claimed the lives of people in more than half of Ohio's counties.
- 04/18/2020
|
Are Ashland Global Holdings Inc.'s (NYSE:ASH) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
- Ashland Global Holdings (NYSE:ASH) has had a rough three months with its share price down 26%. It seems that the...
- 04/18/2020
|
Should Ashland Global Holdings Inc. (NYSE:ASH) Be Part Of Your Dividend Portfolio?
- Is Ashland Global Holdings Inc. (NYSE:ASH) a good dividend stock? How can we tell? Dividend paying companies with...
- 04/18/2020
|
Ladenburg Thalmann Financial Services Inc. Sells 246 Shares of Ashland Global Holdings Inc (NYSE:ASH)
- Ladenburg Thalmann Financial Services Inc. lowered its stake in Ashland Global Holdings Inc (NYSE:ASH) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,452 shares of the basic materials company’s stock after selling 246 shares during the quarter. Ladenburg […]
- 04/18/2020
|
How this Week’s Premium Top 10 Performed, April 17, 2020
- How this Week’s Premium Top 10 Performed, April 17, 2020
Posted by
Greg Harmon
on April 17th, 2020
Each week I post the performance of the stocks that were given to subscribers the previous Sunday. All performance is measured against the plan given t
- 04/17/2020
|
Mapping Ohio’s 9,107 coronavirus cases, updates and trends
- Coronavirus cases of occurred in 87 of Ohio's 88 counties, with deaths in more than half the counties.
- 04/17/2020
|
RPT-Oh brother! Coronavirus calls split family fortunes on Wall St.
- After a calamitous two week plunge in stocks as the coronavirus spread globally, Ricky Sandler called into a midday CNBC show on March 16 with a brash, bullish prediction.
- 04/17/2020
|
Oh brother! Coronavirus calls split family fortunes on Wall Street
- After a calamitous two week plunge in stocks as the coronavirus spread globally, Ricky Sandler called into a midday CNBC show on March 16 with a brash, bullish prediction.
- 04/17/2020
|
Oh brother! Coronavirus calls split family fortunes on Wall Street
- After a calamitous two week plunge in stocks as the coronavirus spread globally, Ricky Sandler called into a midday CNBC show on March 16 with a brash, bullish prediction.
- 04/17/2020
|
Oh brother! Coronavirus calls split family fortunes on Wall St.
- After a calamitous two week plunge in stocks as the coronavirus spread globally, Ricky Sandler called into a midday CNBC show on March 16 with a brash, bullish prediction.
- 04/17/2020
|
Ligocki Joins PPG Board of Directors
- PPG (NYSE:PPG) today announced at its annual meeting of shareholders that Kathleen A. Ligocki, former chief executive officer, Agility Fuel Solutions, LLC, has been elected to join its board of directors, effective immediately. Ligocki will serve on PPG’s board Audit Committee and its Technology and
- 04/16/2020
|
Deutsche Bank Maintains Buy on Ashland Global Holdings, Raises Price Target to $65
|
Ashland sees Q2 EPS above consensus even as revenues slip
- Ashland Global (NYSE:ASH) reports preliminary FQ2 adjusted EPS from continuing operations of $0.84, above $0.76 analyst consensus estimate, on a 9% Y/Y reduction in revenues to ~$610M.Ashland says its
- 04/16/2020
|
Guggenheim Capital LLC Has $9.16 Million Stock Holdings in Ashland Global Holdings Inc (NYSE:ASH)
- Guggenheim Capital LLC lifted its stake in shares of Ashland Global Holdings Inc (NYSE:ASH) by 1.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 119,722 shares of the basic materials company’s stock after buying an additional 1,407 shares during the quarter. Guggenheim Capital LLC […]
- 04/16/2020
|
Ashland sees Q2 adjusted Q2 84c, consensus 75c ASH
- Ashland sees Q2 adjusted Q2 84c, consensus 75c ASH
- 04/16/2020
|
Ashland Had $1B In Available Liquidity At End Of Q2, With $350M In Cash On Hand
|
Ashland Maintains $800M Buyback But Says Does Not Plan On Utilizing Buyback In Present Financial Environment
|
Ashland provides update on fiscal 2020 second-quarter earnings and COVID-19 impact
- Ashland Global Holdings Inc. (ASH) today provided an update for preliminary fiscal 2020 second-quarter financial results, its response to the COVID-19 pandemic, and strong financial position. The Ashland portfolio performed well during the quarter, despite the global macroeconomic uncertainty brought
- 04/16/2020
|
Ashland provides update on fiscal 2020 second-quarter earnings and COVID-19 impact
- Company highlights strong financial position and cash flow; sets date for fiscal 2020 second-quarter earnings release
- 04/16/2020
|
Ashland Global Holdings Inc (NYSE:ASH) Sees Large Decrease in Short Interest
- Ashland Global Holdings Inc (NYSE:ASH) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 1,690,000 shares, a decrease of 31.5% from the March 15th total of 2,465,400 shares. Approximately 2.8% of the shares of the company are sold short. Based […]
- 04/16/2020
|
Ashland Says Plans To Maintain Qtr. Dividend Of At Least $0.275/Share
|
Latin America Cosmetic Preservatives Market to surpass a valuation of $130 million by 2026, says Global Market Insights Inc.
- Selbyville, Delaware, April 15, 2020 -- According to a research report published by Global Market Insights Inc., the Latin America cosmetic preservatives market size was valued.
- 04/15/2020
|
Mapping Ohio’s 7,280 coronavirus cases, updates and trends
- Ohio's coronavirus cases are spread across nearly every county, with 324 deaths
- 04/14/2020
|
WI-Amend-Marsy'sLaw-Cnty
- 04-13-20 19:49, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the voting on the Amendment Marsy's Law. . . . ... . . . . . ... ... ... .. . . ... . ... ... . . . . ... ... TP PR Yes No Adams 20 20 3,561 963 Ashland 34 29 2,048 958 Barron 36 35 7,452 2,639 Bayfield 35 31 3,459 1,771 Brown 112 80 33,580 10,594 Buffalo 23 18 1,703 667 Burnett 24 15 1,937 713 Calumet 48 19 3,200 1,070 Chippewa 46 31 8,673 2,761 Clark 81 73 4,402 1,683 Columbia 37 0 0 0 Crawford 27 10 769 258 Dane 237 103 65,520 27,767 Dodge 59 59 16,231 4,585 Door 42 0 0 0 Douglas 26 26 7,458 2,486
- 04/14/2020
|
WI-SuprCt-Cnty
- 04-13-20 19:49, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the race for Supreme Court. ... ... ... . . . . . ... . . . ... ... . . . . ... ... . . . . ... TP PR Karofsky Kelly Adams 20 20 2,313 2,620 Ashland 34 29 1,969 1,292 Barron 36 35 4,748 5,650 Bayfield 35 31 3,432 2,143 Brown 112 80 24,110 22,213 Buffalo 23 18 1,088 1,281 Burnett 24 15 1,095 1,561 Calumet 48 19 1,920 2,566 Chippewa 46 31 5,462 6,339 Clark 81 73 2,639 3,854 Columbia 37 0 0 0 Crawford 27 10 582 494 Dane 237 103 76,010 24,234 Dodge 59 59 9,402 12,989 Door 42 0 0 0 Douglas 26 26 6,204 4,175
- 04/14/2020
|
WI-GOP-Pres-Cnty
- 04-13-20 17:19, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the Republican primary for President. . ... ... ... . ... . .. ... ... ... ... .. ... ... .. ... . . .. ... . . TP PR Trump Unnstrct Adams 20 0 0 0 Ashland 34 7 477 3 Barron 36 10 1,221 7 Bayfield 35 5 263 4 Brown 112 8 1,886 18 Buffalo 23 0 0 0 Burnett 24 0 0 0 Calumet 48 0 0 0 Chippewa 46 13 2,570 36 Clark 81 6 271 0 Columbia 37 0 0 0 Crawford 27 0 0 0 Dane 237 39 10,529 288 Dodge 59 0 0 0 Door 42 0 0 0 Douglas 26 0 0 0 Dunn 41 6 934 7 EauClaire ..
- 04/13/2020
|
WI-Dem-Pres-Cnty
- 04-13-20 17:19, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the Democratic primary for President. .. ... ... ... ... ... ... ... ... Yang Adams 0 Ashland 0 Barron 1 Bayfield 1 Brown 5 Buffalo 0 Burnett 0 Calumet 0 Chippewa 5 Clark 0 Columbia 0 Crawford 0 Dane 105 Dodge 28 Door 0 Douglas 0 Dunn 2 EauClaire 23 Florence 0 FondduLac 23 Forest 0 Grant 1 Green 0 GreenLake 0 Iowa 0 Iron 0 Jackson 1 Jefferson 18 Juneau 0 Kenosha 29 Kewaunee 7 LaCrosse 3 Lafayette 0 Langlade 0
- 04/13/2020
|
WI-GOP-Pres-Cnty
- 04-13-20 16:19, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the Republican primary for President. .. ... ... .. .. ... ... ... ... ... ... ... . ... ... .. ... ... ... ... TP PR Trump Unnstrct Adams 20 0 0 0 Ashland 34 0 0 0 Barron 36 0 0 0 Bayfield 35 0 0 0 Brown 112 0 0 0 Buffalo 23 0 0 0 Burnett 24 0 0 0 Calumet 48 0 0 0 Chippewa 46 0 0 0 Clark 81 0 0 0 Columbia 37 0 0 0 Crawford 27 0 0 0 Dane 237 0 0 0 Dodge 59 0 0 0 Door 42 0 0 0 Douglas 26 0 0 0 Dunn 41 0 0 0 EauClaire 94 0 0 0 Florence 8 0 0 0
- 04/13/2020
|
WI-Dem-Pres-Cnty
- 04-13-20 16:19, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the Democratic primary for President. ... ... ... ... ... ... ... ... ... Yang Adams 0 Ashland 0 Barron 0 Bayfield 0 Brown 0 Buffalo 0 Burnett 0 Calumet 0 Chippewa 0 Clark 0 Columbia 0 Crawford 0 Dane 0 Dodge 0 Door 0 Douglas 0 Dunn 0 EauClaire 0 Florence 0 FondduLac 0 Forest 0 Grant 0 Green 0 GreenLake 0 Iowa 0 Iron 0 Jackson 0 Jefferson 0 Juneau 0 Kenosha 0 Kewaunee 0 LaCrosse 0 Lafayette 0 Langlade 0 Lincoln 0
- 04/13/2020
|
Mapping Ohio’s 6,975 coronavirus cases, updates and trends
- COVID-19 Cases have been identified in 86 of 88 Ohio counties, with deaths in 46 counties.
- 04/13/2020
|
Ashland Global (NYSE:ASH) Rating Increased to Outperform at BMO Capital Markets
- Ashland Global (NYSE:ASH) was upgraded by investment analysts at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a report released on Monday, The Fly reports. The brokerage currently has a $75.00 price target on the basic materials company’s stock, down from their prior price target of $87.00. BMO Capital Markets’ […]
- 04/13/2020
|
Ashland upgraded to Outperform from Market Perform at BMO Capital ASH
- Ashland upgraded to Outperform from Market Perform at BMO Capital BMO Capital ASH
- 04/13/2020
|
Norges Bank Takes Position in Ashland Global Holdings Inc (NYSE:ASH)
- Norges Bank bought a new stake in Ashland Global Holdings Inc (NYSE:ASH) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 495,581 shares of the basic materials company’s stock, valued at approximately $37,927,000. Norges Bank owned 0.82% of Ashland Global as of its most recent […]
- 04/13/2020
|
BMO Capital Upgrades Ashland Global Holdings to Outperform, Lowers Price Target to $75
|
5 Trade Ideas for Monday: Ashland Global, Chemed, Fiserv, Generac and Global Payments
- 5 Trade Ideas for Monday: Ashland Global, Chemed, Fiserv, Generac and Global Payments
Posted by
Greg Harmon
on April 12th, 2020
5 Trade ideas excerpted
from the detailed analysis and plan for premium subscribers:
Ashland Global, Ticker: $ASH
Ashland
- 04/12/2020
|
Top Trade Ideas for the Week of April 13, 2020: The Rest Premium
|
People’s Bank Reports First Quarter Earnings
- People’s Bank of Commerce (OTCBB: PBCO) announced today its financial results for the first quarter of 2020. The bank reported net income of $1,111,000 or $0.33 per diluted share for the first quarter of 2020 compared to net income of $839,000 or $0.28 per diluted share in the same quarter of 2019. Earnings
- 04/10/2020
|
Mapping Ohio’s 5,878 coronavirus cases, updates and trends
- Ohio's 5,878 coronavirus cases are spread across 84 counties, with 231 deaths.
- 04/10/2020
|
Staying connected: Pandemic puts rural internet to the test
- The novel coronavirus ARS-CoV-2, which causes the COVID-19 disease, continues to spread in countries across the globe after first being identified in Wuhan, Hubei, China, in December 2019. The first
- 04/10/2020
|
Northeast Ohio’s heavy coronavirus toll: more than half the state’s deaths, higher per capita rates
- 12 Northeast Ohio counties account for 36% of Ohio’s population, yet have 51% of the coronavirus deaths and 45% of the cases.
- 04/10/2020
|
Ashland Global (NYSE:ASH) Price Target Cut to $68.00 by Analysts at UBS Group
- Ashland Global (NYSE:ASH) had its target price cut by analysts at UBS Group from $86.00 to $68.00 in a research report issued on Wednesday, BenzingaRatingsTable reports. The firm presently has a “buy” rating on the basic materials company’s stock. UBS Group’s price objective suggests a potential upside of 17.97% from the stock’s current price. Several […]
- 04/10/2020
|
Mapping Ohio’s 5,512 coronavirus cases, updates and improving trends
- Mapping Ohio’s 5,148 coronavirus cases, updates and improving trends
- 04/09/2020
|
Gardiner Angus Ranch Bulls Average $7,334
- In the wake of social distancing guidelines, more than 72% of GAR cattle were sold online, as 633 bidders were registered to bid in person, on LiveAuctions.tv and Superior Livestock Auction.
- 04/09/2020
|
The Current State of Hand Sanitizers: Special Permitting allows Organic Alcohol Company to Donate to First Responders and Highly Vulnerable Citizens
- The Alcohol and Tobacco Tax and Trade Bureau (TTB) has put in place provisions to relieve certain requirements to allow permitted distilled spirits businesses to fast-track the approved production of hand sanitizers in direct response to the Novel Coronavirus – COVID 19. Permitted Distilled Spirit Plants
- 04/08/2020
|
Mapping Ohio’s 5,148 coronavirus cases, updates and improving trends
- All but five of Ohio's 88 counties have had COVID-19 cases.
- 04/08/2020
|
UBS Maintains Buy on Ashland Global Holdings, Lowers Price Target to $68
|
Mapping Ohio’s 4,782 coronavirus cases, updates, trends
- Ohio's 4,782 coronavirus cases are located in 81 of the state's 88 counties. There have been 167 deaths.
- 04/07/2020
|
WI-Amend-Marsy'sLaw-Cnty
- 04-07-20 12:49, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the voting on the Amendment Marsy's Law. .. ... . ... ... ... . . .. . .. ... ... .. ... ... .. ... .. .. ... TP PR Yes No Adams 20 0 0 0 Ashland 34 0 0 0 Barron 36 0 0 0 Bayfield 35 0 0 0 Brown 112 0 0 0 Buffalo 23 0 0 0 Burnett 24 0 0 0 Calumet 48 0 0 0 Chippewa 46 0 0 0 Clark 81 0 0 0 Columbia 37 0 0 0 Crawford 27 0 0 0 Dane 237 0 0 0 Dodge 59 0 0 0 Door 42 0 0 0 Douglas 26 0 0 0 Dunn 41 0 0 0
- 04/07/2020
|
WI-SuprCt-Cnty
- 04-07-20 12:49, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the race for Supreme Court. .. ... ... . .. ... ... ... .. .. ... ... .. ... . ... ... ... ... ... TP PR Karofsky Kelly Adams 20 0 0 0 Ashland 34 0 0 0 Barron 36 0 0 0 Bayfield 35 0 0 0 Brown 112 0 0 0 Buffalo 23 0 0 0 Burnett 24 0 0 0 Calumet 48 0 0 0 Chippewa 46 0 0 0 Clark 81 0 0 0 Columbia 37 0 0 0 Crawford 27 0 0 0 Dane 237 0 0 0 Dodge 59 0 0 0 Door 42 0 0 0 Douglas 26 0 0 0 Dunn 41 0 0 0
- 04/07/2020
|
WI-GOP-Pres-Cnty
- 04-07-20 12:19, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the Republican primary for President. .. ... ... .. .. ... ... ... ... ... ... ... . ... ... .. ... ... ... ... TP PR Trump Unnstrct Adams 20 0 0 0 Ashland 34 0 0 0 Barron 36 0 0 0 Bayfield 35 0 0 0 Brown 112 0 0 0 Buffalo 23 0 0 0 Burnett 24 0 0 0 Calumet 48 0 0 0 Chippewa 46 0 0 0 Clark 81 0 0 0 Columbia 37 0 0 0 Crawford 27 0 0 0 Dane 237 0 0 0 Dodge 59 0 0 0 Door 42 0 0 0 Douglas 26 0 0 0 Dunn 41 0 0 0 EauClaire 94 0 0 0 Florence 8 0 0 0
- 04/07/2020
|
WI-Dem-Pres-Cnty
- 04-07-20 12:19, By The Associated Press Here are the latest, unofficial returns from Wisconsin by county in the Democratic primary for President. ... ... ... ... ... ... ... ... ... Yang Adams 0 Ashland 0 Barron 0 Bayfield 0 Brown 0 Buffalo 0 Burnett 0 Calumet 0 Chippewa 0 Clark 0 Columbia 0 Crawford 0 Dane 0 Dodge 0 Door 0 Douglas 0 Dunn 0 EauClaire 0 Florence 0 FondduLac 0 Forest 0 Grant 0 Green 0 GreenLake 0 Iowa 0 Iron 0 Jackson 0 Jefferson 0 Juneau 0 Kenosha 0 Kewaunee 0 LaCrosse 0 Lafayette 0 Langlade 0 Lincoln 0
- 04/07/2020
|
Amorphous Polyalphaolefin (APAO): Technologies and Global Markets
- The global APAO market has significant scope due to APAO’s wide range of applications and versatility in varied domains such as the automotive, packaging and personal care sectors, among others.This report has been segmented by type, end users, application and geography. The major geographies covered
- 04/07/2020
|
Global Amorphous Polyalphaolefin (APAO) Market (2018 to 2024) - Increasing Demand for Disposable Hygiene Presents Opportunities
- Dublin, April 07, 2020 -- The "Amorphous Polyalphaolefin (APAO): Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering..
- 04/07/2020
|
Alliancebernstein L.P. Has $8.18 Million Stake in Ashland Global Holdings Inc (NYSE:ASH)
- Alliancebernstein L.P. boosted its holdings in shares of Ashland Global Holdings Inc (NYSE:ASH) by 2.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,819 shares of the basic materials company’s stock after purchasing an additional 2,530 shares during the period. Alliancebernstein L.P. […]
- 04/07/2020
|
Is Ardagh Group S.A. (ARD) A Good Stock To Buy?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/07/2020
|
